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SUMMARY 
In addition to identifying the presence of a specific controlled drug in an exhibit and 
measuring its concentration, forensic drug laboratories are requested in certain cases 
or as a routine to provide additional information that may be helpful to the 
investigation process. On the basis of their chemical and physical characteristics, 
seized drugs may be profiled and linked to common sources or routes of 
distribution. 
Chapter 1 is an introduction to the illicit drug production from cultivation to 
manufacturing and trafficking. Chapter 2 describes the role of the drug chemist and 
includes characterisation of seizures, that is identification, quantification, and 
comparison of illicit drugs. Chapter 3 provides a literature review of the different 
analytical methods used in the area of drug profiling. 
This project has been on the subject of drug profiling with focus on the ring-
substituted amphetamine, 3,4 methylenedioxymethamphetamine (MDMA) or 
ecstasy as it is widely called. Among the main objectives of this study was the 
development and optimisation of a new extraction procedure, solid phase extraction, 
for impurities in seized ecstasy tablets. The instrumental analysis of impurities 
found in ecstasy tablets usually require a preliminary process to extract, isolate, and 
concentrate these impurities from the total tablet content. In the process, interfering 
materials are removed, and the required substances are concentrated into a solvent 
that is suitable for introduction into the instrument. Chapter 4 describes the 
development of a solid phase extraction (SPE) procedure and also an evaluation of a 
comparison procedure of liquid-liquid extraction (LLE) and SPE for extracting 
impurities in ecstasy tablets for profiling purposes. Solid phase extraction of 
impurities in ecstasy tablets proved to be more efficient than the traditional liquid-
liquid extraction. SPE provided impurity peaks with higher intensities than did LLE 
and a shorter extraction time. 
Another area of research was the use of infrared technology as an additional tool for 
profiling ecstasy tablets as seen in Chapter 5. Infrared method can serve as an 
elimination or screening step for gross clustering or grouping of exhibits. 
In chapter 6 the synthesis of MDMA using different synthetic routes to acquire 
authentic samples of impurities which are usually present in street samples were 
performed. These authentic samples were analysed and their mass spectra and 
retention indices were used to identify impurities in actual street samples to 
determine their route of synthesis. In chapter 7 ecstasy tablets confiscated within the 
UK were analysed to establish their route(s) of synthesis using the data of the 
authentic compounds synthesised earlier. 
The main contributions of this project were: 
1. Developing a solid phase extraction procedure as an alternative to the conventional 
liquid-liquid extraction procedure. SPE provided extraction with no cross 
contamination of phases and no emulsion problem, as with LLE, due to the presence 
of fatty acids in ecstasy tablets. 
2. Developing a simple and fast infrared method as a screening or elimination tool for 
ecstasy profiling. 
3. Study of the synthetic routes of ecstasy samples within the UK with the aid of route-
specific authentic impurity compounds synthesised in-house. 
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1. ILLICIT DRUGS 
1.1. INRODUCTION 
It is widely accepted that illicit drug traffic and abuse are international problems. 
These problems are international because they cannot be successfully dealt with by 
a country without the co-operation and assistance of others. The contemporary 
economic, political and social developments have significant impact on the illicit 
drug phenomenon. New globalising economic regulations and advances in 
technology have resulted in a more interdependent world. Criminal organisations 
involved in illicit drugs respond to these opportunities created by a more relaxed 
global market of free trade to increase the illicit drug trafficking. Another factor for 
the rise of international drug production and distribution was the political situation 
in many different countries around the world including domestic instability and 
conflicts. The collapse of state structures in many countries has left an institutional 
vacuum which has been exploited by drug trafficking organisations. Illicit drug 
revenues or the drugs themselves are usually exchanged for arms to support the 
different groups involved in armed conflicts. 
1.2. ILLICIT DRUG PRODUCTION 
Drugs of abuse available in the illicit market can be divided into two general 
categories with respect to origin, natural, from plants, and synthetic, from precursor 
chemicals. Natural drugs may be further subdivided into semi-synthetic (e.g. heroin 
or LSD), isolative (e.g. cocaine or hash oil) or plant material (e.g. marijuana). 
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1.2.1. Plant-based drugs 
Plant-base drugs have the largest share of drugs conswned illicitly [1]. In addition 
to the cultivation of cannabis, the plants used in the illicit production of heroin and 
cocaine are opiwn poppy and coca leaf respectively. 
1.2.1.1. Illicit cultivation 
The illicit cultivation percentage as a share of the total arable land has expanded 
dramatically in recent years due to the higher profit margins than with licit crops. 
Figure 1.1 [1] shows the countries with the largest cultivation areas of illicit crops 
relative to arable land in the early 1990s. 
Guat~mala I 
Botswana I 
Swaziland I 
Tajikistan • 
Trinidad. Tobago. 
M~xico • 
Jamaica _ 
Sudan ••• 
Kazakhstan ::::. 
Morocco 
Pakistan ••••• 
l~sotho 
South Africa 
Myanmar 
Colombia 
Bolivia 
Kyrgystan 
lao ""opl~·s D~m. R~p. 
Afganistan 
o 0.5 
_ Illicit cultivation as sharr of arabl~ land. % 
Includ~s opium, coca and cannabis cultivation. 
1.5 2.5 
Figure 1.1. Illicit cultivation as share of arable land in the early 1990s 
Characterisation and Profiling of Ecstasy Tablets Page 3 
Almost 90 % of the world illicit production of opiates originates in two main areas, the 
Golden Triangle (Lao PDR, Myanmar, Thailand) and the Golden Crescent (Afghanistan, 
Pakistan, Iran) [2]. Myanmar and Afghanistan are the two main countries of illicit opium 
poppy cultivation. Other countries with a lesser extent of illicit cultivation are Columbia, 
Mexico and countries of Central Asia. Only about a third of the total illicit production of 
opium gum, which has reached 5000 tonnes in 1996, is thought to be consumed as opium 
[1]. The rest is used in the manufacture of heroin in clandestine laboratories. 
Virtually all of the illicit cocaine produced comes from the Andean regions of three South 
American countries, Bolivia, Peru and Columbia, which together account for more than 
98 % of the world cocaine supplies [3]. Most of the coca leafs used to produce cocaine are 
grown either in the valleys of Bolivia or Peru [4]. The most important supplier of coca 
paste and cocaine base to cocaine hydrochloride laboratories in Colombia is the world's 
leading cultivator of illicit coca, Peru. The amount of coca cultivation in Peru is more than 
that of the other leading coca producing countries, Bolivia and Colombia [4]. In 1996 
about 300,000 tonnes of coca leaf were produced with Peru accounting for half of the 
total global cultivation area. 
Illicit cannabis cultivation is not limited to certain areas as is the situation with coca leaf 
and opium poppy. However, there are certain regions and countries where mass 
cultivation and production is practised including Jamaica, Morocco, Columbia, the USA, 
the Central Asian Republics of the Commonwealth of Independent States, Mexico, 
Afghanistan, Pakistan and the Republic of South Africa. Figure 1.2 [1] illustrates global 
trends in the production of coca leaf, opium poppy and cannabis. 
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Trends in global production 
of illicit drugs (Index: 1985 = 100). 
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Figure 1.2. Trends in the production of coca leaf, opium poppy and cannabis 
1.2.1.2. Illicit production 
After cultivating and harvesting of the illicit crops (coca leaf and opium poppy), the 
production stage of cocaine and heroin takes place. A series of laboratories are 
commonly utilised in processing a drug with each laboratory performing a specific 
stage or stages of production. The manufacturing of injectable heroin employs six 
distinct stages of increasing technical complexity [4, 5]. The first stage involves the 
use of lime and ammonia to extract morphine from opium poppy. The second step 
is the conversion of morphine into heroin, which begins with the bonding of 
morphine and acetic acid into an impure form of diacetylmorphine (heroin). 
Removal of impurities from the compound using water and chloroform is the third 
------ ----- -- --
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step. The final and most difficult stage involves the use of ether and hydrochloric 
for the conversion of heroin into powder form. A high level of technical skill is 
required here to avoid igniting the volatile ether gas. 
Cocaine production is done in three different stages of clandestine processing, pasta 
lab, base lab, and crystal lab as they are called by the clandestine community [6]. 
The coca leaf must first be processed into coca paste, then coca base. Only then can 
the resultant compound be converted into the powdery white substance called 
cocaine hydrochloride. A further stage produces crack cocaine. Traditionally, each 
stage was completed in separate laboratories, but recently this has changed and the 
whole process is condensed into direct leaf-to-base laboratories, by-passing the 
isolation of coca paste [6]. While the paste, base and direct leaf-to-base laboratories 
are usually in the form of isolated, widespread cottage industry including many 
individual units allover the coca-producing regions of South America, the crystal 
laboratories (conversion of coke base to cocaine hydrochloride) are normally larger, 
more sophisticated and centralised [6]. 
A new trend in illicit production is the shift in production sites. In the past most 
heroin was manufactured in Europe near the source of chemical precursors, while 
today much of the production process takes place within the cultivating area. [4]. 
Cocaine processing has also shifted to the immediate growing area. This new shift 
is perhaps a way to increase the unit value of the trafficked substance [4]. 
1.2.2. Synthetic drugs 
Since the mid-l 980s the world has faced a wave of synthetic stimulant abuse. The 
principal synthetic drugs manufactured clandestinely are the amphetamine-type 
stimulants (ATS) which include the widely abused amphetamine and meth-
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amphetamine, as well as the more recently popularised methylenedioxy-
methamphetamine (MDMA), known as ecstasy. Lysergic acid diethylamide (LSD) 
is a synthetic drug also produced clandestinely, whereas sedatives, another type of 
synthetic drug which includes barbiturates and benzodiazepines, are typically 
diverted from licit channels. A TS are now consumed in almost every region of the 
world as seen in figure 1.3. Synthetic drug abuse, particularly A TS are on the 
increase worldwide. For example, methamphetamine abuse is more widespread 
than that of cocaine in the countries of the AsialPacific region and used more often 
than heroin in many other countries. In several European countries consumption of 
ecstasy and amphetamine is greater than that of heroin and cocaine [1]. 
As opposed to drugs from plants, synthetic drugs can be manufactured from 
chemicals which can be found or produced almost anywhere in the world. Therefor 
trafficking distances are much less than the distances required in the production of 
plant-based drugs. This nature of illicit manufacturing will not only reduce risk, but 
reduce trafficking and input costs as well, resulting in much larger gross profit 
margins [7]. Although the illicit production for both plant-based and synthetic drugs 
behave similarly in certain ways, such as the same characteristics of illegality and 
risk, they do have crucial differences in that geographical determinants are much 
less important. 
Because of the above differences of the nature of the illicit synthetic industry 
within plant-based manufacturing, greater profits will result, and the coming years 
will witness significant expansion in the illicit synthetic drugs industry and 
consequently higher consumption patterns. 
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Figure 1.3. Global illicit use of ATS 
1.2.2.1. Clandestine manufacture of synthetic drugs 
The discovery of clandestine drug laboratories is becoming increasingly common. 
These laboratories have increased the mobility of the individuals involved. It is not 
uncommon for them to cook up a batch, make a sale, discard the equipment and 
chemical residues onsite, and move on to continue the process at another location. 
The problem of clandestine laboratories for manufacturing illicit drugs is 
experienced in many countries around the world. Amphetamine and 
methamphetamine manufacturing premises have been seized in Denmark, Iran, 
Mexico, the Netherlands, Belgium, the United States, Gennany, Korea, Sweden, 
Canada, and the United Kingdom [8]. Detection of the number of laboratories 
where drugs are produced illegally can serve as an indicator of illicit drug 
production. For example, methamphetamine was the drug produced in 84% of the 
seized clandestine laboratories in the US in the 1990s, 94% of Colombian illegal 
laboratories produced cocaine, and most Polish laboratories manufactured heroin 
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from poppy straw [1]. A TS laboratories detected worldwide exceeded those of both 
heroin and cocaine over the period 1991 - 1994. Around 55% of the total seized 
laboratories worldwide involved in ecstasy production were located in Europe. 
Illicit drug manufacturing poses great adverse effects and can have dangerous 
consequences including placing people at risk of exposure to toxic chemicals. 
Chemicals used in the manufacturing process can be corrosive, explosive, 
flammable, toxic and possibly radioactive. Exposure can occur via absorption, 
inhalation, ingestion or injection. Generally there are two health hazards associated 
with clandestine laboratories, criminal hazards (e.g., violence) and chemical hazards 
(e.g., use oftoxic or flammable substances) [9]. 
1.2.2.2. Environmental problems 
Environmental problems associated with illicit cultivation are numerous although 
relatively little attention has been given to this issue [4]. Numerous scientific studies 
conducted to date describe the negative consequences related to the loss of the 
world's tropical forest resources. The cultivation of illicit narcotic crops such as 
coca, opium poppy and cannabis has contributed to the forest removal and water 
and soil pollution. Illicit cultivation has a share in the tropical deforestation and 
environmental damage. In Peru, the leading illicit coca cultivator, there are around 
125,000 hectares devoted to coca cultivation [4]. Growers commonly plant their 
illicit crops in fragile forest environments in remote areas. Moreover, chemicals 
used by many growers at all stages of illicit drug cultivation and production are 
dumped onto the land and into small streams, rivers and water bodies polluting 
almost all the surrounding areas. 
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1.3. TRAFFICKING AND DISTRIBUTION 
Type of drug usually governs the trafficking pattern worldwide. This ivolves many 
different transit countries or forms of transport, some trafficking routes are complex 
and reflect the criminal efforts to avoid law enforcement authorities (figure 1.4). 
_ Cocaine t. .... fficking routltS 
c:::> Coca cult ivation .~.s 
-
• 
Heroin traf'fic:king rout~ 
Opium poppy cultlv.tion 
ereas 
Figure 1.4. International trafficking of cocaine and heroin [1]. 
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Trafficking is the crucial link in the chain between illicit drug production and 
consumption. The distribution stage of the illicit drug industry accounts for the 
highest percentage of the gross profit as seen in figure 1.5. 
H",roin traffick",rs (90%) 
_ Processors (2%) 
_ Farm",rs (6%) 
_ Opium vad",rs (2%) 
Figure 1.5. Gross profit of different levels in the chain of heroin industry [1]. 
The most important cost in this large industry in terms of number of participants and 
turnover with considerable profit margins, is risk, both personal and to the product. 
Because of the illicit nature of this trade the transactional cost accounts for the highest 
proportion of the total cost [1]. Production and distribution of illicit drugs have seen 
notable increase despite defections and arrests. This is mainly attributed to two main 
factors, high profit margins and ability to innovate and maintain operations. The illicit 
drug industry has shown high level of organisation including the use of advance 
technologies and new methods of smuggling. 
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2. ROLE OF THE DRUG CHEMISTRY LABORATORY 
2.1. INTRODUCTION 
Every examination made by a forensic chemist has potential legal consequences. 
Forensic chemists must be prepared to depart from the familiar natural science 
setting of the laboratory and enter the confrontational setting of the courtroom and 
be able to communicate with the legal system. The forensic chemist must be able to 
explain the significance of complicated analytical procedures to individuals with 
little or no scientific training. If the forensic analyst is to have any credibility on the 
witness stand, he must be able to describe what he has done in terminology 
understood by those individuals with whom he is communicating. There are three 
main objectives of forensic chemistry, identification, quantification and comparison 
of different exhibits. 
2.2. IDENTIFICATION OF CONTROLLED SUBSTANCES 
The materials sent to the drug section of a forensic laboratory may be divided into 
two classes. The first class comprises pharmaceutically manufactured legal 
preparations, usually tablets or capsules suspected to be illegally possessed or 
misused, and illicitly prepared tablets. The second class contains materials which 
lack characteristic external properties, usually powders and sometimes solutions. 
The most dangerous drugs generally belong to this class as well as clandestinely 
manufactured tablets. 
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Controlled substances sold on the street are usually mixed with adulterants and 
diluents in a crude and mostly unspecified manner. In some laboratories, the 
analysts are required to identify and quantitate both the controlled substances and 
the adulterant drugs and diluent materials. Once the analysis has been completed, it 
must be documented. The final report must be clear and accurate, with all 
conclusions supported by analytical data. The data may be in the form of notations 
on paper in the analyst's writing or on instrumental printout. Each time a report is 
signed, the analyst places his reputation and credibility before the strict test of the 
court and the careful look of his peers. Discovering a mistake after the report has 
been submitted to the court is not good. 
Whenever a controlled substance is identified, the possibility exists that an 
individual could be imprisoned or suffer some other legal consequences as a result. 
There is, therefore, an absolute requirement for high degree of certainty in the 
identification of controlled substances. An example of this requirement is seen 
when the law in some countries requires certain conclusions as to whether an 
exhibit is the base or salt form for sentencing purposes, as is the case with cocaine 
seizures. In this case, a variety of instrumental techniques can be used to distinguish 
cocaine HCI from cocaine base. FTIR spectroscopy is commonly used in many 
laboratories for this purpose. The IR spectra of cocaine HCI and cocaine base are 
quite different and easily distinguished. 
Most street drug samples contain adulterants and diluents. Adulterants are 
chemicals added to illicit drugs which can give some sort of physiological response. 
This response can range from very mild to quite severe. Diluents are chemicals 
added to controlled substances which are used more as fillers than to elicit a 
physiological response. They can be added to affect the colour and composition for 
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the sake of satisfying the user. Adulterants and diluents are usually added to the 
controlled substance mixture by those involved in illicit distribution. Samples taken 
from large scale (kilogram seizures) will be relatively pure. Adulterants are 
encountered, in increasing proportion, as the illicit drug progress down the 
distribution chain from the main supplier to the dealers to the users. 
Identification of adulterants and diluents mayor may not be a requirement as a part 
of the identification scheme in the forensic science laboratory. In most cases, the 
requirements of the legal system will be limited to the identification of the 
controlled substances. While adulterants are, in most cases, organic substances with 
similar chemical properties and can therefore be detected and identified in a similar 
manner as to the controlled drugs, diluents such as sugars, carbohydrates, starch, 
sodium chloride and calcium carbonate, can be simply identified by microscopic 
procedures. Chemical separation, however, is also fairly easy because most diluents 
are usually insoluble in solvents such as diethyl ether or hexane, and only slightly 
soluble in methanol. Once separated by organic extraction from the main drug 
mixture, they can be identified using IR if only one diluent is present or HPLC in 
the case of a mixture of diluents. 
Even if the identification of all adulterants, diluents and other by-products are not 
required in the final report generated by the analyst, such information can prove 
useful in evaluating trends and possible distribution patterns. 
2.3. QUANTIFICATION 
There are several reasons why quantitative analyses of drugs are needed. Firstly, in 
some legislative systems, the penalty for drug crimes is affected by the 
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concentration of the controlled substances in seizures. Secondly, sudden changes in 
the drug content (purity) may imply serious threat to the user, especially as far as 
such highly toxic drugs as heroin and cocaine are concerned. In order to monitor 
these changes, quantitative analysis of street drugs are needed. Thirdly, such 
analyses will also establish possible common origins of drug seizures. Matching 
seizures may then be subjected to closer comparison [10] using methods described 
in the following section and in chapter 3. 
A number of different methods can be used to quantitate controlled substances. 
Capillary column GC and HPLC are probably the two most utilised instrumental 
methods to accomplish this task. The most common analytical method for 
quantitation involves the use of an internal standard, providing a consistent 
concentration of a known chemical in solution. The internal standard method is 
especially advantageous because the detector response for the internal standard to 
the drug can be checked for each injection. 
The basic demands for quantitative analysis are accuracy and precision. The ability 
to measure the true value or the closeness of the measured value to the true value 
for a sample is the accuracy of the method [11-15]. Accuracy is usually determined 
in several ways: 
o by analysing a sample of known concentration such as a certified reference material 
and comparing the measured value to the true value or, 
o by comparing the results from the new method with results from an established 
reference method. 
The precision of an analytical method is the amount of scatter in the results obtained from 
multiple analysis of a homogeneous sample. It is the degree of agreement among 
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individual test results when the procedure is applied repeatedly to multiple aliquots of a 
sample. 
Precision can be divided into three components, I) system precision: the precision of the 
actual measurement independent of the sample preparation process, 2) method precision: 
this step involves the sample preparation considerations (at least six aliquots from a 
homogenous sample mixture should be analysed), 3) day-to-day precision: allows for a 
complete assessment of method performance. 
An accurate method of low precision will give a mean result close to the true value. 
However, a large number of determinations would be needed to achieve this and that is a 
disadvantage from a practical point of view. It may be said therefore, that good accuracy 
requires good precision. 
In quantitative analysis the analyst needs to know how the response measured depends on 
the analyte concentration. The linearity assessment determines the procedure's ability to 
obtain test results which are proportional to the concentration of the analyte in the sample 
within a given range either directly or via a well defined mathematical transformation [12, 
16]. 
2.4. COMPARATIVE ANALYSIS 
Two different kinds of controlled substance analysis are routinely conducted in the 
forensic science laboratory. The first is identification, to identify a controlled 
substance by name. The second, less common, type of analysis is comparative 
analysis. Its purpose is to determine a commonality of source. A comparative 
analysis will include a comprehensive examination of the sample's chemical and 
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physical characteristics, with a goal of demonstrating, with a high degree of 
certainty, a common origin for two or more samples. 
In forensic examination of illicit drugs, it is possible to state with a high degree of 
certainty that two exhibits of a white powder share a common source. The wording 
in stating such a conclusion is critical. Words must be carefully selected in order to 
convey the conclusion clearly and concisely, without overstepping the scientific 
certainty that exists. The following quote, about two samples of cocaine, is from the 
transcript of drug trial held in 1991. It illustrates the appropriate language to be used 
on such occasions. 
After a review of all analytical data, it can be stated that with a high level of 
scientific certainty and beyond a reasonable doubt that a close chemical 
relationship exists between (the two samples) strongly suggesting that they were 
derived from the same manufacturing process ... and that they were probably 
derived from the same batch [J 7]. 
Before undertaking a detailed examination of two samples, a broad overview is 
desirable. The colour and granularity of the exhibits should be examined, and then 
the components of the sample identified and quantitated. The second procedure 
involves the evaluation of the process by-products and trace materials in the 
exhibits. It is important to realise that for successful evaluation of two exhibits to 
determine commonality of source, each exhibit must be analysed in the same way 
using the same methodology and instruments, and chemicals and solvents from 
same containers. 
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Controlled substances such as heroin and cocaine are the simplest to compare 
because they are derived from botanical substances (opium poppy and coca leaf) 
[18]. Many naturally occurring by-products from the plants are carried through the 
processing stages of the drugs, and these can be used to confirm the existence of a 
common source. 
The investigation of relationship in the field of drug analysis is an important task in 
forensic chemistry for court evidence and drug intelligence. Common source of 
drug seizures is typical example of such relationships. The methods used for this 
purpose were reviewed [19, 20] and may be divided into groups according to the 
following scheme. 
A. Physical or "ballistic" methods for comparing items having characteristic external 
properties, e.g. tablets and capsules. 
B. Chemical analysis 
1. Inorganic chemical methods for the display of trace element profiles. 
11. Organic chemical methods. 
(a) Identification of impurities characteristic of the synthetic route (key impurities) 
which may establish relationship with precursor chemicals. 
(b) Comparison based on the analysis of the chemical composition for the 
establishment of common sources. 
1. Comparison based on chemical signatures (impurity profile) 
2. Comparison based on the analysis of known main constituents. 
Other methods have also been reported including isotope ratio determination to 
cluster many different seizures into smaller groups or determine the country of 
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origin for some drug samples, enantiomeric determination using chiral columns or 
chiral agents, and qualitative and quantitative determination of residual solvents in 
illicit drugs. Chapter 3 contains detailed discussion on these methods. 
2.5. CLANDESTINE LABORATORIES 
Clandestine laboratories are generally divided into two types. The first is the 
operational clandestine laboratory. This laboratory, usually operating in secrecy, is 
engaged in the production of controlled substances, precursors to controlled 
substances, or controlled substances analogues. The second is the non-operational 
clandestine laboratory. This usually is a storage facility that is under investigation 
because of information obtained from precursor and essential chemical monitoring 
[21]. 
The forensic chemists may be asked to provide assistance in preparing search 
warrants based on available information, such as knowledge that certain chemicals 
and pieces of analytical equipment such as gas cylinders, and glassware, such as 
large triple neck round bottom flasks, have been purchased [22]. This sort of 
information is critical in determining what kind of synthesis is taking place. The 
forensic scientist will also provide technical advice regarding the importance of 
specific safety considerations and offer suggestions on handling situations such as 
on-going reactions [21]. 
After the clandestine laboratory site has been secured by the appropriate law 
enforcement authorities, the forensic scientist may enter the site to evaluate the 
environment and decide on the most appropriate action. The forensic analyst will 
begin to sample, package, and mark evidence containers. This process will usually 
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proceed slowly and methodically to ensure accuracy and completeness [8, 22]. 
Once the clandestine laboratory has been seized and the evidence collected, the 
forensic analyst will proceed to the laboratory in an attempt to identify as many of 
the samples as deemed necessary for the required legal action. This may mean 
identifying all exhibits that were seized, or it may mean that only those exhibits 
required to form a conclusion as to an identification of the final product are 
necessary. The extent of the analysis can be more of a legal question than a 
scientific question. The forensic scientist should be able to provide the basics of the 
reaction mechanisms. This information will be based on the chemicals at the site 
and those identified in the reaction mixture. He should also be able to provide the 
theoretical yield of the final product based on the amounts of the chemical 
precursors. 
After the work in the laboratory has been completed, the forensic scientist has the 
responsibility of assisting the legal authorities in understanding what was happening 
in the clandestine laboratory, what was being synthesized and details of the 
synthetic method. The forensic analyst must recognise his responsibilities as an 
expert witness and provide factual information in as much detail as necessary. 
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3. ILLICIT DRUG COMPARISONS / PROFILING 
3.1. INTRODUCTION 
Drug exhibits in crime laboratories are often present as illicit preparations or as 
counterfeits of brand-name pharmaceutical products. They are usually encountered 
in various fonns such as powders, tablets or capsules. 
Many drug traffickers and dealers mix their supply, which may be already cut, with 
physiologically active or inactive substances. Various unintentional impurities such 
as starting materials, synthesis by-products and residual solvents are also present as 
a result of poor quality control in clandestine laboratories. Substances usually found 
in illicit drugs other than the active constituent are classified as follows: 
1. Cutting agents: adulterants are pharmacologically active substances added to 
compensate for the lack of the illicit drug (e.g. diamorphine). Among the most 
common are paracetamol, caffeine, phenobarbital, and local anaesthetics [23,24]. 
Diluents on the other hand are pharmacologically inactive substances added to 
drugs to increase bulk (e.g. sugars, starch, com flour, and talc powder) [23,24]. 
2. Impurities: _They are substances found in illicit drugs in trace amounts and are of 
two origins, natural: occur naturally as constituents of natural drugs such as opium 
and coca leaf; synthetic: constituents in the starting materials, impurities of side 
products and unreacted starting materials [23]. As a chemical reaction proceeds, 
various impurities are fonned which accumulate because of the lack of quality 
control in illicit manufacture and are present in the finished drug product [5]. 
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Drugs of abuse can be divided into two general categories with respect to origin; 
natural, from plants, and synthetic, from precursor chemicals. Natural drugs may be 
further subdivided into semi-synthetic (e.g. heroin or LSD), isolative (e.g. cocaine 
or hash oil) or plant material (e.g. marijuana or khat). 
In addition to identifying the presence of a specific controlled drug in an exhibit and 
measuring its concentration, forensic drug laboratories are requested in certain cases 
or as a routine to provide additional infonnation that may be helpful to the 
investigation process. On the basis of their chemical and physical characteristics, 
seized drugs may be profiled and linked to common sources or routes of 
distribution. 
The characterisation and classification of illicit drug samples is an important 
objective for drug intelligence, It establishes relationships between seizures and 
may provide evidence of links between dealers and users. Not only does this allow 
the matching of samples in local cases of dealing but also provides intelligence 
information on the origin and distribution of samples which may be of use in 
investigating major trafficking operations. The overall purpose for the comparative 
analysis [25] is to drive a strategic and/or tactical intelligence. Strategic (macro 
level), intelligence refers to the derivation of general processing origins, for 
example, where and how a seized drug was manufactured. This allows for 
determining trafficking trends (Figure3.1). Tactical (micro-level) intelligence refers 
to the derivation of case specific links, relating samples to a common batch and 
allowing for sample/sample comparison (Figure 3.2) . 
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Figure 3.1. Strategic intelligence. Impurity profiles for heroin samples from 
different regions. [25] 
Scientists, specialising in illicit drug analysis in criminal or other analytical 
laboratories have been using many different approaches in the area of illicit drug 
characterisation / profiling since the early 1970s. These approaches varied 
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according to the drug nature and the analytical philosophy or needs. Samples 
coming into laboratories in tablets or capsule form are usually subjected to physical 
analysis or so called "ballistics". Other exhibits such as powders are subjected to 
chemical analysis, which can be organic or inorganic. Inorganic analysis of illicit 
drugs is concerned with the determination and comparison of the elemental content 
in exhibits. Organic analysis on the other hand is more varied with different types of 
analysis and approaches available to the forensic chemist. There are many different 
types of organic analysis performed by analytical laboratories, which are involved 
in illicit drug characterisation and profiling: 
1. Determination and quantification of impurities or minor components present in the 
seized drug, which originate from precursors, natural raw materials, solvents used in 
the synthesis, and side-reaction and intermediates. 
2. Measurement of naturally occurring isotopic ratios. 
3. Determination of diastereoisomeric or enantiomeric composition of drug exhibits 
4. Determination of residual solvents for comparative analysis 
5. Identification and quantification of the principal controlled drug(s) and cutting agents 
present in the exhibit. 
6. Drug profiling using infrared spectrometry 
Characterisation and Profiling of Ecstasy Tablets 
oLr ~. 
0 
-. 
~ lL 
o 
o 
b 
., .L l, J 
10 
tlmt,nn 
~ JI 
10 
timl, min. 
~.ll .~ J.. 
20 
b 
IlL.. IJ 
Page 24 
a b 
f-" ~. . LI .1, 0 
0 10 20 
(A) time, min. 
«DXJ -. b 
o f- _1.&.~~L ......... jIUotLlI1. . ... ~ t ... , ... 1.... , 1_ 
J 10 JJ 
(B) tint. nin. 
Figure 3.2. Tactical intelligence. (A) Two samples from different cases identified as 
coming from the same batch. (B) Two samples from same case identified as coming 
from same batch. 
This chapter provides a review of published reports carried out by many workers in the 
field of illicit drug characterisation and profiling. Most of the reports cited were 
concerned with heroin, cocaine, and amphetamines (amphetamine, methamphetamine, 
and 3,4-methylenedioxyamphetamine and analogues). Reports reviewed include 
experimental analysis used such as analytical instruments and systems, extraction 
procedures, and computer software including statistical analysis. 
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3.2. PHYSICAL METHODS "BALLISTICS" 
These methods are used for comparing items having characteristic external 
properties, e.g. tablets, capsules and fractured hashish cakes. Physical analysis of 
illicit drug preparations is largely limited to tablets and capsules, although 
occasionally other seizures received considerations. For tablets, the examination 
involves firstly the determination of gross characteristics of the preparation such as 
shape, diameter, thickness and weight. Other features, such as the groove depth and 
width, bevell angle and groove or score angle, can be studied by the use of 
microscopic means [26]. Secondly, low power microscopy is used to detect minute 
"punch" marks which are transferred to the tablet from the punch used during the 
manufacturing procedure; these serve to identify a tablet with a particular set of 
punches. The marks on the tablet are a result of the damaged areas of the punch 
faces. These marks are normally seen on the groove faces and bevelled edges of a 
tablet. Capsules on the other hand are less easy to identify and examinations are 
usually limited to the determination of size, shape, locking features, colour, etc. 
Only physical tests that involve accurate measurements are of value for the 
comparison of illicitly produced tablets. The success of a physical analysis of drug 
exhibits depends on considering some critical requirements [19], such as adequate 
numbers of exhibits, proper handling (e.g. storing at stable conditions, maintaining 
physical integrity) and building up a database of authentic materials. Normally, two 
or more physical analysis are performed on the same exhibit resulting in an 
orthogonal technique for establishing connectivities [27]. 
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3.3. CHEMICAL METHODS 
These methods are normally used for the analysis of items lacking characteristic 
external properties such as powders or solutions, but have also been applied to other 
samples such as tablets and plants. Chemical analysis for the characterisation of 
illicit drugs normally involves the following procedures: 
3.3.1. Inorganic analysis 
A study of inorganic impurities provides additional information to the impurity 
profiling of illicit drugs. Elemental analysis of drugs can be helpful in giving 
information regarding geographic origin, synthetic route, and type of refining 
treatment used plus direct sample/sample comparison [28]. Inorganic analysis is a 
simple and effective method for profiling illicit drugs [29]. Trace elements 
(inorganic impurities) analysis provides some advantages over organic analysis 
including the following: 
1. no storage decomposition as is the case with many organic substances [30], 
2. difficulty comparing and classifying samples based on their organic impurities 
rather than their inorganic impurities if the drug exhibit is very pure [31], 
3. high cost of maintaining organic impurity profiling methods and acquiring data 
[32]. 
Study of the elemental concentrations in drug exhibits can provide unique 
information regarding the raw materials used and manufacturing procedures 
employed [33]. 
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Trace element profiling has been successfully applied to many different matrices 
including food products [30], where the geographic origin determination analysis 
was performed for orange juice, pistachio, and macadamia nuts, diamond, gold and 
drugs of abuse, i.e. methamphetamine (figure 3.3 ) [29, 34, 35], heroin [28, 32] and 
sodium gamma hydroxy butyrate (GHB) [29]. 
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Figure 3.3. ICP spectra for methamphetamine hydrochloride [36] 
Inductively coupled plasma, ICP with atomic emission spectrometry, AES [33] or 
mass spectrometry, MS [28, 29, 31, 32, 34, 35] was the analytical tool 
predominantly used for trace elements analysis. Heroin sample were prepared by 
dissolving in nitric acid [28,29,32], or hydrochloric acid after being dry-ashed [33], 
methamphetamine samples were dissolved in deionised water [31, 34, 35] and 
cocaine samples in HCl. Other instruments such as atomic absorption spectrometry 
(AAS) [34] and ion chromatography [31] were also used. Statistical analysis usually 
follows elemental analysis to provide a better means of presenting data in the form 
of cluster analysis [34] as shown in Figure 3.4 or dendograms [32] as illustrated in 
Figure 3.5. 
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Figure 3.5. Dendrogram from individual analysis from separate heroin seizures [32] 
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3.3.2. Organic Analysis 
3.3.2.1. Analysis of impurities (minor components) 
Clandestinely manufactured drugs often contain impurities in trace amounts. As a 
chemical reaction proceeds, various impurities are formed which may accumulate 
because of the lack of quality control in illicit manufacture [37] as seen in Figure 
3.6. Impurities are of two origins; natural (constituents of natural drugs such as 
opium and coca leaf), and synthetic (constituents in the starting materials, 
precursors side products solvents and intermediates) [5]. The determination and 
quantification of these impurities provides a great deal of information to the drug 
analyst for the characterisation and comparison of drug exhibits. It reflects 
precursor chemicals, synthetic routes, common origin, and trafficking trends. 
Origin of Impuritie in Illicit Drugs 
( Irom~'1! Mnd \laehl~. 1979) 
Figure 3.6. Origin of impurities in illicit drugs [37] 
3.3.2.1.1. Identification of impuritie 
Identification of impurities present in clandestinely manufactured drugs often 
pro ides information on the precursor chemicals used and synthetic routes 
employed. ertain impurities identified in illicit drugs are route specific impurities 
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(e.g. intermediates). Identification of impurities for the purpose of establishing the 
synthetic route has been reported for amphetamine [38-44], methamphetamine [45-
49], 3,4-methylenedioxy-methylamphetamine, MDMA, [50-56], heroin [23, 57-60], 
and cocaine [24, 61-64]. 
Heroin: 
Heroin is manufactured via the direct precursor, morphine, from the dried milky 
juice obtained from the ripe flower pods of Papaver somniferum, opium. Opium 
contains many natural alkaloids including morphine, narcotine (noscapine), 
codeine, papavarine and thebaine. 
Morphine was first isolated from opium in 1805 while the first synthesis of 
diacetylmorphine (heroin) was reported in 1874. Due to its wide abuse early this 
century, it was controlled in 1925 and the first clandestine manufacture of heroin 
subsequently began in China [5]. 
Since heroin is manufactured from morphine, the latter is extracted from opium 
using various processes, such as the Thiboumery and Mohr process, the Robertson-
Gregory process, the Barbier process, the Heumann process, the Schwyzer 
modification of the Robertson-Gregory process, and the Merk process. The majority 
of clandestine laboratories followed the Thiboumery and Mohr process [5]. Once 
the morphine is produced, synthesis of heroin follows (Figure 3.7). 
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SYNTHESIS OF HEROIN [52] 
HO H3C 0 
i! :1 
'I 
acetic 0 
I 0 :/ 
" 
anhydride 
CH3 
0 / 
" 
N 
------~ CH3 0 N 
HO H3C 0 
Morphine Heroin (diamorphine) 
Figure 3.7. The acetylation of morphine to produce heroin. 
Because of lack of quality control in the clandestine manufacturing of heroin and 
with no purification steps used for the final product, many impurities originating 
from opium, formed during synthetic reactions and/or coming from chemicals used 
in the process are carried over and are present in the final product. The main 
impurities encountered in illicit heroin samples are listed in Table 3.1. 
Some heroin manui'acturlng hnpurltl __ 
1. Meconin 
2. Hydrocotarnine 
3. 3.8_dln,".thoxy-4.5-epoxyphenan-
thren& 
4. T'hebaol 
5. O"-acetylthebaol 
8. 4.6_diacetoxy-3-rnethoxyphenan-
thrane 
7. (E)_3_[2_(2_N_rnethyl_ 
acetarnido) .. thyl)-4.5-
rnethylenedloxy-6-rn .. thoxy-
phenyl] acryliC acid 
8. Papaverine 
9. O".N_diacatyl_a_norcodirnethln .. 
10. 
11. 
12. 
13. 
14. 
16. 
16. 
17. 
O".N_dlacatyl_a_norrnorphlrnethln .. 
O".N-dlacetylnorcodeln .. 
N-acetylnorrnorphine 
O~~~~-';~t~~~~ 
O".N_dlacetylnorrnorphlna 
4_acetoxy_3.8·dlrnathoxy-5-[2_(N_rnethyl_tarnldo»)ethyl-
phenanthrene 
O'".O"_N_trlaoetyinorrnorphln .. 
4.6_dlacetoxy_3_rnethoxy_5_ (2_(N_rnethylac:etarnldo)]-
ethylphenanthrene 
., B. N-acetylnorlaudanoa.ne 
19. Papaveraldlne 
20. Death.balne 
21. 4.B--dlacetoxy-3-rnathoxy-S-[2-(N-rnethylac.tarnldo»)-
ethylphenanthrane 
22. Narootine 
23. 4-acetoXY-3.6-dlrnathoxy-S-(2-(N-rnathylacatarnldo)]-
ethyl phenanthrene 
24. N-acetylnornarcotln. 
25. 4.6-dlacetoxy-3-fTlathoxy-6-(2-(N-rn_hylacetarnido»)-
..thylphenanthrene 
26. (E)-N-acetytanhydronornarce'n_ 
27. ("I A. 98)-1 -aoatoxy-N-aoatyl-
1.9-dihydroanhydronornarce'ne 
28. (Z)·N-acety'.nhydronornarc.'n_ 
29. (1 A.9A)-1-.. c .. toxy-N-...... tyl-
1 .9-ctihydroanhydronornarc.'n_ 
30. O"-rnonoacatylrnorphine 
31. O"-rnonoacetylrnorphlne 
32_ .... -acetoxy-3.6-dil'1"t8thoxy-
phenanthrene 
33. N_O-diacetylnorcod.ine 
Table 3.1. Impurities detected in illicit heroin exhibits [5] 
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Relating heroin samples to common origins on the basis of the impurities present was 
reported for narcotine and norlaudanosine-related manufacturing impurities using a one-
step extraction procedure and capillary gas chromatography [59]. Acidic and neutral 
impurities in illicit heroin, analysed by capillary electrophoresis, were also reported [60]. 
Using reversed-phase HPLC, 06-monoacetylmorphine, acetylcodeine, noscapine, and 
papaverine [23] were also detected and identified. Huizer [57] provided a study of the 
formation of 0 3 -monoacetylmorphine during heroin production and during its hydrolysis. 
Also in another study [58] quantitative and qualitative determinations of some naturally 
occurring opium alkaloids were used to draw conclusions about the common origin of 
different samples. 
Cocaine was first isolated from coca leaves by Albert Niemann who gave it the name 
cocaine in around 1860. Coca leaves grow in two main regions, the Far East (Indonesia, 
Taiwan, and Sri Lanka) and South America (Colombia, Peru, and Bolivia). The latter is 
the source of most cocaine in the world. The Far Eastern leaves have low content of 
cocaine and are not known to be involved in the illicit market [5]. Cocaine is also 
produced from total synthesis. However, the majority cocaine found in the illicit market 
is not from this source because the synthesis requires a degree of expertise not easily 
found in clandestine laboratories. 
CLANDESTINE COCAINE PROCESSING 
The flow chart below (Figure 3.8) describes three different stages of clandestine 
cocaine processing, pasta lab. base lab. and crystal lab as they are called by the 
clandestine community [6]: 
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The start is in the pasta lab where 100 to 150 kg of dry leaves are soaked in water. 
A strong base is then added to force the nitrogenous alkaloids into an organic phase 
(gasoline or kerosene) resulting in an alkaloid mixture which consist of cocaine, cis 
& trans-cinnamoylcocaine, tropine, tropacocaine, hygrine, cuscohygrine, ecgonine, 
benzoylecgonine, methylecgonine, and sterioisomers of truxillines, truxinic and 
truxillic acid, methyl benzoate, benzoic acid, cinnamic acid, and soluble organic 
plant waxes. After an addition of mineral acid (such as sulfuric or hydrochloric 
acid), the organic solution of alkaloids is precipitated as alkaloid salts. 
The crude cocaine salt produced in the pasta lab is passed to the base lab or directly 
to the crystal lab. In the base lab a further purification is performed by potassium 
permanganate oxidation of cis & trans-cinnamoylcocaine. An overoxidation usually 
result in the formation of N-formyl cocaine which means reduced profits. This is 
why the base lab stage is sometimes omitted. 
In the final stage ( crystal lab) crude cocaine is converted to cocaine hydrochloride 
by dissolving it in a solvent such as ether followed by the addition of hydrochloric 
acid. These solvents are sometime detected in cocaine hydrochloride samples and 
contribute another parameter for cocaine comparison and profiling. 
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Figure 3.8. Cocaine production process. 
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Impurities in illicit cocaine samples were also detected and results were used to relate 
samples. Comparison of illicit cocaine samples by determination of the main coca 
alkaloids cocaine, cis-cinnamoylmethylecgonine, and trans- cinnamoylmethylecgonine 
using two HPLC systems [24] was reported. The identification ofN-formyl cocaine [61], 
and norcocaine, N-benzoylnorecgonine methyl ester, and N-formyl norcocaine [62], 
which originate from using potassium permanganate to oxidise impurities in the cocaine 
processing procedure, was used to characterise illicit cocaine samples. The absence of N-
formyl cocaine indicates that no potassium permanganate was employed [61]. The 
identification of the common minor alkaloids of E. coca in illicit cocaine samples means 
that the cocaine is natural [64]. Baugh et al [65] provided an excellent review of 
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impurities encountered in illicit cocaine samples. Table 3.2 gives a list of major impurities 
in cocaine samples. 
impul'ities in illicit cocaine 
1. I-cocaine 10. l-norcocaine 
2. ecgonine 11. N-formylnorcocaine 
3. ecgonidine 12. N -benzylnorecgonine 
4. benzoyl ecgonine 13. cis-cinnamic acid 
5. trans-cinnamoylcocaine 14. cis-methyl cinnamate 
6. cis-cinnamoylcocaine 15. benzoic acid 
7. truxiline 16. methyl benzoate 
8. truxilic acid 17. hygrine 
9. tropacocaine 18. cuscohygrine 
Table 3.2. Compounds associated with cocaine exhibits from natural sources 
Amphetamine 
1 
The Leuckart amphetamine synthesis has been the most popular method for the 
production of amphetamine in the U.K., U.S.A. and The Netherlands and other 
European countries [40,41,47]. Other methods such as the reductive amination of 
benzyl methyl ketone and the allylbenzene route have also been used [47] (Figure 
3.9) 
Phenyl8cetone 
~o 
H 
o 
+ I 
HC-ONH. 
Heat 130-11O"C 
3brs 
~::!!!! .. ---... ()( 
Amphetamine 
1. Leuckart reaction 
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phenylacetone (P2P) 
2. Reductive amination of P-2-P 
C~CN 
AlJylbenzene Acetonitrie 
~CH, 
o HNycH, 
o 
N-Acetylamphetamine 
3. Allylbenzene route 
1. Sulfurincld 
Figure 3.9. Routes of amphetamine synthesis. 
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amphetamine 
o 
N-Acetylamphetamine 
Amphetamine 
The detection of 4-methyl-S-phenylpyrimidine indicates that the sample was 
synthesised by the Leuckart method [40, 44]. Isolation by repeated TLC using 
various solvent mixtures and identification by mass spectrometry and IH and BC 
NMR of two pyrimidines, five pyridines, and one pyridone in illicit amphetamine 
was reported [42]. Knowledge of these impurities helps avoiding interference by the 
by-products in analytical technique [43]. Figure 3.10 shows a typical Leuckart 
amphetamine impurity profile. Reviews of the most common synthetic routes for 
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manufacturing amphetamine and impurities identified have also been published [38, 
39,47]. 
Figure 3.10. Leuckart amphetamine impurity profile. A, amphetamine; B, 4-methyl-
5-phenylpyrimidine; C, N-benzylamphetamine; D, diCB-phenylisopropyl)amine; E, 
N-methyl-diCB-phenylisopropyl)amine; F, N,N-diCB-phenylisopropyl)formamide 
[66] 
Metb:tmthtamine 
Methamphetamine is synthesised by various routes, e.g., reductive amination of 
benzyl methyl ketone, Leuckart reaction [47], and from ephedrine [45] as illustrated 
in Figure 3.11. Other routes are the allylbenzene route [49] and the phenylacetic 
acid route [48]. 
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Figure 3.11. Synthesis of methamphetamine from different routes 
Many impurities were detected as route-specific impurities such as iodoephedrine, 
1,2-dimethyl-3-phenylaziridine from the ephedrine route [45], I-phenyl-2-bromo-
propane, an intermediate from the allyl benzene route [49], and N-formylmethyl-
amphetamine as a route specific impurity from the Leuckart reaction [47]. 
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Detennination of route specific impurities has led to the conclusion that the 
methamphetamine abused in Japan is prepared from ephedrine [46]. 
Several dozen analogs of amphetamine and methamphetamine came out in the 
1960s and became more widely abused in the early 1980s. They were called 
designer drugs. Designer drugs are produced in clandestine laboratories to mimic 
the psychoactive effects of controlled drugs. Among the most widely known 
designer drugs is MDMA. 
MDMA 
MDMA, called "Adam," "Ecstasy," and other names in the street, is a synthetic 
drug. Its chemical structure (3-4 methylenedioxymethamphetamine) is similar to 
two other synthetic drugs, MDA and methamphetamine, which are known to cause 
brain damage. It was first synthesized in 1914, rediscovered and became popular as 
a recreational drug in early 1980s. MDMA is an analogue of MDA and it is related 
to both amphetamine and mescaline. Although it is often referred to as a 
psychedelic drug, it also possesses stimulant properties. As a free base MDMA is a 
white, musty smelling oil with a searing taste, insoluble in water but soluble in most 
organic solvents[67]. 
Clandestine production of 3,4-methylenedioxymethamphetamine, MDMA was 
discussed in detail [56]. Many different synthetic routes such as the reductive 
amination route, the Leuckart method, the bromopropane route, the Ritter reaction, 
the nitropropene route and the cinnamic acid route were reviewed. Safrole, 
isosafrole, piperonal, and 3,4-methlyenedioxy phenyl-2-propanone are the main 
precursors used. MDMA is always illicitly manufactured [51, 54] and because of 
the lack of quality control in clandestine laboratories, impurities arising from 
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precursor chemicals, intermediates and other impurities are also produced and will 
be present in the final product. In a review [51], mass spectral data of impurities in 
MDMA samples synthesised by the reductive amination route, the Leuckart 
reaction, the nitropropene, and the bromopropane route were reported. Impurities in 
illicit MDMA samples were also isolated by TLC and detected by mass 
spectrometry and IH-NMR [54]. Renton et al [52] provided data for precursors, 
intermediates and reaction by-products in illicit MDMA. They used these results for 
establishing the route of synthesis in items received in casework. Verweij reported 
[50] the structural elucidation of impurities in illicit MDMA prepared by the low-
pressure reductive amination of 3,4-methlyenedioxy phenyl propanone with 
methylamine. The presence of the intermediate imine (1,2-methylenedioxy-4-2-N-
methyimino propyl benzene) provided information about the synthetic route. 
Chapter 6 provides a comprehensive overview of the synthesis used in the 
manufacture ofMDMA and impurities detected and identified. 
3.3.2.1.2. Comparison and classification o/impurity profiles (signatures) 
A second different method of comparative analysis is the detailed examination of 
co-extracted constituents of natural plant materials as well as impurities in synthetic 
drugs originating from synthesis, such as precursor chemicals, reaction by-products, 
intermediates and others. The results of this analysis often in the form of 
chromatograms, are called chemical signature, impurity profile, or chemical 
fingerprints. Such analysis can provide vital information concerning batch or source 
relation comparison, grouping drug exhibits into classes or determination of 
geographic origin of seized drugs for investigative purposes, court testimony, and 
drug intelligence. Cluster analysis of impurity profiles of drug exhibits allows the 
classification of exhibits into smaller groups (Figure 3.12), hence providing 
important information to drug intelligence. The importance of source of supply 
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identification and origin of seized drugs determination was recognised at an 
international drug expert group meeting [68]. Drug signature profiling has been 
defmed [69-71] in the literature. 
Cl ... I ca. •• m 
-----~--- -.-----.-----
o 10 on.. 1 __ 1 3D :JO 
Figure 3.12. Grouping heroin exhibits into classes (smaller groups). [72] 
The same expert group meeting concluded that it was feasible to use chemical 
characterisation of heroin for the purpose of identifying source of supply and trafficking 
trends [68] Many workers developed methods for heroin impurity profiling using gas 
chromatography [72-76] and using a capillary-to-capillary column-switching system [77]. 
HPLC was also used to profile acidic and neutral impurities in heroin samples [78] and 
basic impurities using an ultraviolet and a fluorimetric detector simultaneously [79]. 
Sample preparations using a robotic automated system and derivatisation with 
trimethylsilylation (TMA) [72], involving extraction of impurities from acidic solution by 
toluene [76], were reported. The advantage of using toluene [80] is that acidic and neutral 
extracts contain smaller amounts of heroin and other amines. 
Characterisation and Profiling of Ecstasy Tablets Page 42 
In a recent paper [81] new cocaine profiling methodology was reported. The authors aim 
was to achieve a chromatographic profiling methods specifically comparable to human 
fingerprinting and DNA profiling techniques. Impurity profiles for sample/sample 
comparison in a court case has been described [17]. Gas chromatography with flame 
ionisation detector has been widely used but nitrogen-phosphorus [82], and electron 
capture [18] detection have also been used. An HPLC method for cocaine profiling has 
also been described [83]. Cocaine samples comparison using computer programs and 
different statistical approaches are found in the literature [81, 82, 84-86]. Some used a 
pattern recognition technique of comparing the Euclidian distances between samples [85]. 
Others developed [86] neural network pattern recognition software which was found to be 
superior to conventional statistical methods such as correlation, maximum likelihood, etc. 
and distance functions classifications, for example, nearest neighbour, clustering, etc. 
The first synthetic drug to undergo comparative analytical studies was amphetamine [87]. 
In that study and in others [88] impurity profiles (chromatograms) were compared 
visually. A visual method was used at first for comparison of impurity profiles, then and 
because of increasing numbers of samples profiled it became more difficult to perform 
comparison and classification of samples. The use of computer programs based on 
statistical analysis such as, quotient method [89] for comparison on batch level or in 
combination with principal components [90] for cluster analysis (high level classification) 
were discussed. Other computerised methods reported for classification and cluster 
analysis were base on principal component and nearest neighbour [66] and pattern 
recognition methods and SIMCA [91]. Comparison procedures using computerised 
methods will allow for consistent decision rules compared to the inevitable element of 
subjectivity associated with visual methods and are also faster and more economical than 
the visual ones [91]. Most studies on amphetamine profiling reported the use of gas 
chromatography with FID [37, 66, 92-94]but others have used HPLC with solid phase 
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extraction of impurities [95] and with automated extraction and analysis using column-
switching techniques [96]. 
Methamphetamine is widely abused in the United States and Japan [97], and is the 
mostly seized drug in Australia [98]. Among the first published works for profiling 
methamphetamine [99] used capillary GC with flame ionisation and nitrogen 
phosphorus detection. In that study, acidic-extraction for the analysis of impurities 
was used. However, acidic extract of methamphetamine seized in Japan provided no 
GC peaks [46]. Methods for comparing impurity profiles included the use of 
Euclidian distance [97, 98, 100] cluster analysis using SAS [101], Systat for 
Windows and other in-house programs [102]. 
3.3.2.2. Measurements of isotope ratios of naturally occurring isotopes 
Characteristic isotopic composition is acquired by molecules from starting materials 
as they undergo synthetic and biosynthetic pathways. The isotopic composition or 
ratios constitute their own isotopic signature. During the synthetic process the 
isotopic signature can either evolve with or without intentional modification. 
Therefore, organic substances provide specific isotopic signature originating from a 
natural or synthetic source allowing for precise determination of origin [102]. On 
this basis, measurements of the isotopic ratios of isolative and plant drugs such as 
cocaine and cannabis respectively, can be done to establish origin authentication. 
Carbon isotope ratios provide information regarding the botanical origin while 
oxygen and hydrogen isotope ratios give information on environmental conditions 
under which the plant was cultivated [102]. In the case of drugs of semi- synthetic 
origin where the isotopic signature is effected by the synthesis process, the isotope 
ratio is linked to both the natural (geographic) origin and to the synthesis process as 
the case with manufacture of heroin from natural opium or morphine via acetylation 
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[103]. With synthetic drugs such as amphetamine, the isotopic ratio is linked to the 
chemicals used in the synthesis and will allow for establishing batch relation of 
exhibits. 
Measurement of isotope ratios can give vital information for tracing trafficking 
routes. Early reports on isotope ratio determination include the work done by Liu et 
al [104] who tried to obtain isotopic information regarding the geographical origin 
of cannabis by measurements of carbon isotope ratios from both leaves and flowers 
of the plant. They concluded that cannabis grown indoors and in a metropolitan area 
contain lower I3 e content. Since heroin is a diacetylated derivative of morphine , 
information regarding the geographical origin are derived from the morphine 
moiety of the molecule while information regarding the illicit laboratory is provided 
by the acetyl moiety. Reports on isotope ratios determination of heroin to establish 
geographical origin and lor relate samples to a common source or batch has been 
cited [103, 105-108] 
Mean lJC enrichment of heroin from various geographical 
origins 
Origin 
Turkey a 
Unknown b 
Niger a 
Thailand a 
Pakistan a 
India a 
III n _ 9. b n - 12. 
Mean DC 
enrichment 
-33.561 
- 31.302 
- 32.154 
-32.173 
-32.322 
- 31.568 
95% confidence 
interval 
- 33.822 to - 33.300 
- 31.504 to - 31.100 
- 32.416 to - 31.893 
- 32.493 to - 32.853 
- 32.583 to - 32.061 
- 31.892 to - 32.306 
Table 3.3. Mean l3e enrichment of heroin from different geographical origins [106] 
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The Comparison of isotope ratios for heroin samples from different countries was 
described using GC-IRMS (Figure 3.13) [105]. Heroin 13 C enrichments (Table 3.3) for 
each origin were compared using two-sample t-test. In another study [106] confiscated 
heroin samples were clustered into four different groups according to diacetylmorphine 
and acetylcodeine 13 C enrichments. Isotopic fractionation due to morphine acetylation 
was determined [103]. The isotopic fractionation showed differences of the 13 C 
enrichment for morphine (raw material) and heroin suggesting that utilisation of the 13 C 
analysis of heroin may be unsuitable for determination of heroin samples origin. Thus a 
single morphine sample acetylated with two different acetic anhydrides will probably 
yield two diacetylmorphine samples with two different 13 C enrichments. 
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Figure 3.13. Schematic diagram of the gas chromatograph-isotope-ratio mass 
spectrometer [102] 
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In another report 3,4-methylenedioxy- methyl amphetamine samples were classified 
into smaller groups [109] after determination of their isotope ratios by measuring 
I3C enrichment. Further discrimination was possible using 15 N / 14N isotopic ratios. 
3.3.2.3. Differentiation and classification of drug samples using isomeric procedures 
Isomers are compounds with the same molecular formula and are classified as 
either enantiomers or diastereomers. Enantiomers are isomers which are mirror 
images of each other with identical physical and chemical properties. Diastereomers 
are not mirror images of one another and have similar, but not identical physical 
and chemical properties. Figure 3.14 shows a diagram of isomerism. 
In recent years, the identification and quantitation of enantiomers of controlled 
substances have received a great deal of forensic attention. Because of differences 
in pharmacological effects and government regulatory measures, forensic science 
analysis of optically active drug samples face unique challenges and controversies. 
The development of analytical methods suitable for the differentiation and 
determination of optically active drugs is more than an academic exercise or useful 
only for clinical or pharmacokinetic studies; it fills apparent forensic analytical 
needs. The enantiomeric ratios may provide intelligence information on batches of 
illicitly produced drugs or their origin or route of synthesis [110-112]. It has been 
reported that certain drugs derived from a natural source usually exist as one 
enantiomeric form, and clandestine produced drugs, are usually a mixture of 
enantiomers. Thereby it is possible to classify a sample as to being of either natural 
or synthetic origin by isomeric determination [64]. 
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Figure 3.14. Chart of isomerism. 
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Furthermore, analysis of the composition of isomers (if present) may differentiate 
samples prepared under different synthetic conditions. For example, identification 
of I-ephedrine in optically pure d-methamphetamine is an indication of the synthesis 
of d-methamphetamine from I-ephedrine. 
Several approaches have been described for enantiomeric analysis including 
chromatographic methods, NMR and infrared technology. 
3.3.2.3.1. Chromatographic methods 
Gas and liquid chromatography and capillary electrophoresis have been used to 
separate enantiomers [110, Ill, 113-117]. Separations have been achieved by the 
use of either chiral stationary phase or by chiral derivatising reagents. 
Characterisation and Profiling of Ecstasy Tablets Page 48 
3.3.2.3.1.1. Gas chrunatugraphy, GC 
Methamphetamine enantiomers were determined using chiral and achiral capillary 
columns on a gas chromatograph / mass spectrometer (GC-MS) system [115]. 
Samples, a seized methamphetamine and a simulated illicit methamphetamine 
synthesis product, were derivatised with N-trifluoroacetyl-I-propyl chloride (/-
TPC). The conclusion drawn was that the resolution on an achiral column is 
adequate for the determination of methamphetamine enantiomers and impurities, 
providing the enantiomeric purity of 1-TPC is known. In another paper [110] the 
enantiomers of methamphetamine, ephedrine, pseudoephedrine and methcathenone 
were determined by gas chromatography after derivatisation with R-(+)-a-
(triflouromethyl)phenylacetic acid (MTPA). Casale [113] reported a method in 
which pseudoecgonine was detected and resolved from ecgonine in illicit cocaine 
samples by narrow-bore capillary gas chromatography. The detection of 
pseudo ecgonine in illicit cocaine can be used for comparing samples from a 
common source. A comparative gas chromatographic determination of total 
isomeric truxilline manufacturing impurities / by-products in illicit cocaine samples 
was outlined [118]. These isomers were alpha-, beta-, delta-, epsilon-, gamma-, 
omega-, zeta-, peri-+neo- and epi-truxilline. 
3.3.2.3.1.2. LiquidchrunatugratJ;y, HPLC 
High-performance liquid chromatography was used extensively for the 
enantiomeric analysis of illicit drugs [111, 114, 117, 119]. With the use of a chiral 
crown ether column (CROWNPACK CR (+», d-amphetamine and I-amphetamine 
were separated by HPLC analysis without using any derivatising agents prior to 
analysis [117]. A small amount of d-amphetamine (0.1 %) was detected in a 
methamphetamine sample which gave an indication that there was a possibility of 
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illicit synthesis. Chiarotti et al [114] described an HPLC method to separate cocaine 
and pseudococaine using a chiral stationary phase (Supelcosil LC-urea) and 
acetonitrile as mobile phase. A chiral derivatising agent, 2, 3, 4, 6-tetra-O-acetyl-~­
D-glucopyranosyl isothiocyanate (GITC), was successfully used [111] to 
simultaneously resolve R, R-( -)-pseudoephedrine, S, S-( + )-pseudoephedrine, R, S-(-
)-ephedrine, S, R-(+)-ephedrine, S-(+)-methamphetamine, and R-(-)-
methamphetamine using a standard achiml C-18 stationary phase with 
tetrahydrofuran (THF) / water (3:7) as the mobile phase. 
3.3.2.3.1.3. E/ectrojJxJresis, CE 
Chiral analysis by capillary electrophoresis was successfully applied by several 
authors for ring-substituted amphetamines [116], methamphetamine [120, 121], 
amphetamine [120, 122] and cocaine [123]. Lurie [122] reported a MEKC 
separation of amphetamine, methamphetamine, and their hydroxyphenylamine 
precursors, after derivatisation to form diastereoisomers. Fanali [124] described an 
application for amphetamine, using cyclodextrins (CD) which have the ability to 
provide direct chiral separation of a vast spectrum of compounds. Tagliaro et al 
[116] optimised a direct chiral capillary electrophoresis method based on ~-CD for 
the separation of amphetamine, methamphetamine, MDA, MDMA, and MDEA. 
Lurie et al [125] also separated amphetamine, methamphetamine, and other 
stimulants of forensic significance (including cathine, cocaine, propoxyphene and 
others) by using mixtures of neutral (2,6-di-O-methyl) and anionic (sulfobutyl 
ether) ~-CD. The use of chiral separations of drugs offers a flexible, reproducible 
and robust methodology, which, could become the first choice analytical technique 
[124]. 
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3.3.2.3.2. Nuclear Magnetic Resonance, NMR 
There are four different approaches used in the NMR detennination of enantiomeric 
composition. The first two are perfonned before the use of chiral lanthanide shift 
reagents. Derivatising enatiomers with a chiral reagent [126] is one approach and 
combination of enantiomers with a chiral solvent [127] to induce a chemical shift 
difference between corresponding enantiomeric groups is another. The third 
approach [128] involves the use of a chiral solvent and an achiral lanthanide shift 
reagent. The fourth approach employs optically active shift reagents to induce 
nonequivalent NMR spectra of enantiomers [129]. 
Enantiomeric compositions have been reported for norpseudoephedrine, 
norephedrine, and cathinone [130], and ephedrine, pseudoephedrine, 
methamphetamine, and methcathinone [110] using NMR with a chiral solvating 
reagent, (R)-(+)-I,I-bis-2-naphthol. A conclusion was drawn [110] that synthesis 
batches of methcathinone may be differentiated on the basis of the enantiomeric 
data obtained. 
3.3.2.3.3. Infrared methods 
Few articles are found in the literature on the use of infrared methods for the 
enantiomeric detennination of illicit drugs. However, it has been reported that 
infrared method can be very a useful tool for enantiomeric detennination in seized 
drugs [112, 131]. 
Identification of chiral salt fonns that can precipitate from the reaction of chiral 
amines with chiral organic acids has been reported using Infrared spectroscopy. 
Distinct crystalline phases for a single enantiomer, and for a racemic mixture of the 
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two enantiomers can be formed by many chiral substances [131], thereby, allowing 
clear distinction of the two samples by condensed phase infrared transmission 
spectrum. Chappell [112] described a method for enantiomeric determination of 
methamphetamine which, employs an infrared transmission spectrometry technique 
on solid samples dispersed within an alkali metal halide matrix. 
3.3.2.4. Determination of residual solvents for comparative analysis 
Almost, all illicit amine-based drugs are manufactured and distributed as salts [10]. 
The manufacture process involves the use of concentrated acids such as 
hydrochloric acid, to provide a rapid precipitation resulting in crystal matrices 
containing significant quantities of trapped solvents [6]. Qualitative and quantitative 
analysis of these residual solvents may provide vital information for intelligence 
purposes including comparison of different exhibits. In addition, it is important for 
drug enforcement agencies to get updated information of new solvents used in illicit 
drug preparations to allow for more control of their availability. 
The detection and identification of residual solvents in illicit heroin [132-136] and 
cocaine [132, 133, 137, 138] has been described using different analytical tools. 
Proton nuclear magnetic resonance was used to determine solvent residues in illicit 
cocaine samples [137]. The internal standard 1,4-diacetylbenzene was used because 
it exhibits high and low field singlets and also aids in the comparison of the 
integration values of the signals of the solvents to that of the internal standard. The 
five most common solvents identified were benzene, toluene, acetone, methyl ethyl 
ketone and ethyl ether. Two other solvents, methyl chloride and ethyl acetate, were 
also detected for the first time in cocaine exhibits. GC-FID was employed for the 
analysis of occluded solvent residues in cocaine and heroin samples [133] after 
elution with carbon disulphide. The occluded solvent residues were first trapped by 
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solid phase adsorption of headspace vapours onto activated charcoal. Up to 16 
solvents were identified in the cocaine samples and 12 solvents were detected in the 
heroin samples (Figure 3.15). Using this infonnation allowed for comparison of 
different cocaine exhibit however, relating heroin samples was more problematic. 
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Figure 15. Chromatogram of solvent standards identifted in 
cocaine and heroin samples in this study. Elution order: 
1, acetaldehyde; 2, methanol; 3, ethanol; 4, acetone; 
S, isopropanol; 6, diethylether; 7, dichloromethane; 
8, methylacetate; 9, carbon disulphide; 
10, methylethylketone; 11, ethylacetate; 12, hexane; 
13, chloroform; 14, butanol; 15, benzene (from carbon 
disulphide); 16, methylisobutylketone; 17, toluene; 
18, m & p-xylene; 19, o-xylene; 20, n-decane (internal 
standard); 21, 1,2,3-trimethylbenzene. 
Static headspace-gas chromatography-mass spectrometry (SHS-GC-MS) [132] was 
utilised to identify and quantitate residual solvents in cocaine and heroin samples. 
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Aqueous sodium sulfate (22 %) was used for solubilisation of the crystals and 
ensured liberation of the trapped solvents. Solvents detected are listed in table 3.4. 
Cocaine HCI (% of Samples)a 
Methyl Ethyl Ketone (65%) 
Hexanes (61 %) 
Toluene (59%) 
Benzene (55%) 
Acetone (52%) 
Methylene Chloride (41 % ) 
Xylenes (31 %) 
Ethyl Ether (31 %) 
Cyclohexane (27%) 
Ethyl Acetate (23%) 
aNumber of samples = 75. 
bNumber of samples = 826. 
Heroin HCI (% of Samples)b 
Ethyl Acetate (81 % ) 
Acetone (57%) 
Ethyl Ether (34%) 
Methyl Ethyl Ketone (25%) 
Toluene (25%) 
Xylenes (19%) 
Ethanol (10%) 
Isopropanol (5%) 
Hexanes (3%) 
Methyl Acetate (3%) 
Table 3.4. Encountered occluded solvents in illicit cocaine HCI and heroin HCI. [132] 
3.3.2.5. Active drug(s) and cutting agents content to compare exhibits 
Several reports appeared in the literature describing various methods for 
comparison of drug exhibits or predicting their country of origin based on the 
concentration and ratios of selected alkaloids and adulterants present in seized 
substances [10, 52, 139-143]. Detennination of the source of supply or origin of 
illicit heroin samples was established [142] using a method based on the content of 
morphine and codeine and acetyl products and the ratio between them. The author 
noticed that the theoritical ratio of heroin to acetycodeine increased by two-fold at 
each stage during the opium-morphine-heroin process. Opium samples of known 
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origin showed significant variation in the heroin to acetylcodeine ratio, thereby 
allowing the author to have distinct composition profiles of the alkaloids for each 
geographical area. This information made it possible to compare heroin samples of 
known origin with unknown seized heroin samples and also determine the place of 
origin. King [10] concluded that it was possible to distinguish Turkish heroin from 
other South West Asian types on the basis of the acetylcodeine / noscapine ratio. He 
also elaborated on the importance of the drug content of a tablet / capsule or the 
purity of an illicit powder to support a comparative analysis to link two or more 
samples. In another report [141] the detection of arsenic in opium and strychnine in 
opium and heroin samples was found as an approach for the possible identification 
of their source in the local market and their origins of import. 
Recently, the use of statistical analysis using available computer software have been 
outlined [139, 140]. The first report [139] utilised a multivariate statistical analysis 
of the concentration of selected alkaloids and adulterants in seized material. Table 
3.5 lists the alkaloids and adulterants included in the study. The other report [140] 
described a method for numerical comparison of street samples based on Fisher's 
linear discriminant analysis following analysis of the opiate, papaverine and 
noscapine content of the samples. 
Alkaloicls 
6-Acety\codeine 
6-Acety1morphine 
Diamorphine 
Noscapine/Narcotine 
Papaverine 
Adulterants 
Caffeine 
Methaqualone 
Paracetamol 
Phenobarbitone 
Table 3.5. Component of heroin used for the statistical analysis [139] 
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3.3.2.6. Drug profiling using infrared spectrometry 
Infrared spectroscopy and in particular fourier transform infrared, FTIR, can serve 
as another tool for comparing drug seizures. Each exhibit has its own characteristic 
spectrum, and comparison between the different spectra gives a gross estimate of 
the similarity or dissimilarity between the different exhibits [36, 144-146]. 
FTIR has some discriminating capability to classify powders into a large number of 
groups, and consequently can be used for gross comparison of ecstasy exhibits. 
FTIR has some advantages over chromatographic methods such as reduced sample 
handling, faster analysis time, no need for impurities extraction and concentration 
procedure, and lack of volatility, solubility, thermal stability or column limitation. 
Early works on comparison of illicit drug samples [144] using infrared technologies 
reported development of a spectrum compensating technique. In this method a 
wedge disk for one of the components in the drug mixture is prepared. The 
component spectrum is then subtracted from the mixture spectrum. In another study 
on comparison of heroin seizure [36], 419 heroin exhibits were compared among 
them and were clustered into sub groups based on similarities of spectra. The 
method of classification utilised an algorithm for Euclidean distance and library 
search facilities. Figure 3.16 shows a library search result. Visual examination of 
spectra was used as a confirmation to the library search results. 
Classification of some common drug groups, including amphetamine, barbiturates 
and opiates using a multivariate analysis of infrared spectra was also reported [146]. 
Cluster analysis, principal component analysis, and nonmetric multi dimentional 
scaling elements of a computer program were used to structure taxonomic distances 
between drugs. A procedure was developed [145] to separate carbohydrate diluents 
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from active drugs in order to identify them by FTIR. Once determined, diluents 
were useful for comparing different drug exhibits. 
Rashed et al [147] reported a method for profiling ecstasy tablets through the use of 
fourier transform infrared spectroscopy (FTIR). Around 47 ecstasy tablets plus 
standards of MDMA, glucose, lactose, and caffeine were used for the study. 
Samples prepared as KBr disks were analysed directly without any extraction 
procedures or other sample preparations. Library search facilities were used to 
compare spectra using an algorithm of correlation coefficient. The library search 
provided best fits or closest matches from the library spectra to the unknown 
spectrum. A higher number means a closer match (1 being the highest and 0 being 
the lowest). 
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Figure 3.16. FTIR library search of a powder exhibit [36] 
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3.4. DISCUSSION 
Impurity profiling procedures have dominated the illicit drug comparison methods. 
Two main approaches have been reported, (i) identification of trace impurities for 
establishing synthetic routes and identification of precursor chemicals used in 
synthesis and (ii) comparing impurity profiles (chemical signatures) to establish 
drug origin, grouping, and sample-to-sample comparison. Impurities formed during 
the manufacturing process can lead to a danger to the public health. The unintended 
production of I-methyl-4-phenyl-l, 2,5,6-tetrahydropyridine, MPTP in the process 
of manufacturing I-methyl-4-phenyl-4-propionoxypiperidine, MPPP, a heroin 
substitute, has been linked to symptoms of Parkinson's disease [5]. Lead poisoning 
in methamphetamine samples was also discussed [138]. 
Drug profiling usually consists of three main steps: extraction and concentration of 
trace impurities from the drug exhibit, analysis of extracts (chromatography) and 
data interpretation using computers and statistical analysis. Harmonisation of 
analytical condition in profiling analysis is an important issue, which should include 
selection and quantification of marker impurities for comparison procedures, 
synthesis of these impurities, and finally determination of impurity peaks that are 
characteristic to the synthetic route. Profiling using more than a single analytical 
technique with regard to instrumentation would provide better results. To combat 
continuous development in clandestine manufacturing of illicit drugs, identification 
of new synthesis routes and new precursors and chemicals should be regarded as a 
priority in profiling programs. It is worth noting that profiling generally is a costly 
procedure that requires dedicated analytical systems and well-trained experienced 
analysts. 
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3.5. FUTURE DEVELOPMENT 
Notable advances in impurity profiling analysis have been established since the 
early days of these programs. Liquid/liquid extraction procedures are used in 
laboratories engaged in illicit drug profiling and GC-FID has been the method 
mostly used in profiling analysis. New developments sought in drug profiling 
should include: evaluation of new extraction techniques for drug profiling, such as 
SPE [148], SPME, mix phase cartridges, exploring new analytical tools, e.g. CE, 
NMR, IR, and fmally continuing development of new statistical and computerised 
methods for data interpretation and comparison. 
3.6. CONCLUSION AND AIMS OF THE STUDY 
This chapter reviewed published papers on the area of drug profiling. Methods 
reported on this subject include: physical analysis, impurity profiling procedures, 
measurements of isotopic ratios, use of infrared technology for drug comparisons, 
elemental analysis and determination of diastereoisomers and enantiomers to 
differentiate samples. Other methods were also discussed such as analysis of 
solvents in drug exhibits, comparison of drug samples using statistical procedures to 
calculate the main constituents of an exhibit including adulterant, diluents and the 
active drug(s). These methods provide vital information to the forensic chemist in 
addition to the usual conclusion that the exhibit contains a controlled substance or 
not. It allows for comparative analysis between two or more samples, determination 
of the geographic origin of drug exhibits, estimation of the clandestine 
manufacturing and illicit drug trafficking and distribution trends and it provides 
information on precursor chemicals used in illicit drug synthesis which will allow 
for their control. 
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Among the main objectives of this study was the development and optimisation of a 
new extraction procedure such as solid phase extraction, for impurities in seized 
ecstasy tablets. Another area of research was the use of infrared technology for 
profiling ecstasy tablets since only chromatographic methods have been studied. 
Identification of impurities in ecstasy tablets confiscated within the UK was also 
described. Synthesis of MDMA using different synthetic routes was performed to 
acquire authentic samples representing impurities normally encountered in street 
samples. These authentic samples were analysed and their mass spectra and 
retention indices were used to identify impurities in actual street samples. 
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4. SOLID PHASE EXTRACTION FOR ECSTASY 
PROFILING 
4.1. INTRODUCTION 
Illicit ecstasy tablets produced in clandestine laboratories usually contain various 
impurities such as reaction by-products, intermediates and contaminants within 
reagents, which accumulate as a chemical reaction proceeds because of the lack of 
quality control in these laboratories. These impurities represent a very small portion 
of the total weight of the illicit tablet. Therefore, dissolving the tablet in an aqueous 
medium or in an organic solvent and directly performing an analysis would not 
yield satisfactory results. 
The instrumental analysis of impurities found in ecstasy tablets usually requires a 
preliminary extraction process to extract, isolate, and concentrate these impurities 
from the total tablet content. In the process, interfering materials are removed, and 
the required substances are concentrated into a solvent that is suitable for 
introduction into the instrument. The impurities found in illicit tablets are extracted, 
after crushing the tablet and dissolving the fine homogeneous powder in de ionised 
water or buffer solution which forms an aqueous matrix, into an organic solvent. 
Although lengthy and time-consuming, these procedures are of paramount 
importance to remove the principal component(s), diluents and adulterants, and 
concentrate impurities. 
Liquid-liquid extraction (LLE) of impurities from the bulk drug has been the 
method for sample preparation for quite some time. It is an isolation and separation 
method based on the distribution between two immiseble solvents that are in close 
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contact with one another [149]. Many problems are associated with this method 
including lengthy handling time and the need to concentrate the sample after 
extraction [95]. 
As a consequence of the above-mentioned problems sample preparation techniques 
using aliquid-solid approach or as it is widely called solid-phase extraction (SPE) 
have been developed and used extensively. SPE is a sample preparation technique 
that uses disposable extraction cartridges containing bonded sorbents, to selectively 
and efficiently extract specific compounds from complex mixtures. SPE is different 
than LLE, which often results in variable sample recovery in that it is based on 
specific molecular interactions for more reproducible results [150]. The main 
advantages ofSPE over LLE are summarised below: [151-154]. 
1. Speed. 
2. Selectivity (The variety of bonded chemical moieties provides the selectivity 
needed to extract a particular compound from potential interferences in a complex 
matrix) and versatility (readily adaptable to automation). 
3. Efficiency (no cross contamination of phases and no emulsions problem). 
4. Reduction of solvent use (reduce the cost of hazardous waste disposal). 
5. Reduction of labour-intensive procedures. 
6. SPE is 5-fold less costly than LLE. 
Several other reports provided comparisons of LLE and SPE. Rood [155], 
compared deposition of sample residues from urine extracts by LLE and SPE 
methods for drugs of abuse and found that samples extracted by the liquid-liquid 
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method contaminated the chromatographic system to a greater extent and much 
faster than those extracted by SPE method. 
Solid-phase extraction (SPE) procedures have been used with various types of 
samples, from biological fluids to environmental pollutants. Many articles on this 
type of work are published in the literature, but only one paper has been cited on the 
use of SPE for the extraction of impurities present in illicit drugs [95]. In this 
project special emphasis will be given to the use of SPE for the extraction of 
impurities in illicit (ecstasy) tablets. This chapter emphasises optimisation of 
profiling procedure for ecstasy tablets which includes sample preparation steps and 
evaluate a comparison of LLE and SPE for extracting impurities from ecstasy 
tablets for profiling purposes. 
4.2. REVIEW 
4.2.1. Solid-Phase Extraction (SPE) 
Solid-phase extraction (SPE) is an approach in which solid-phase adsorbents are 
used as the media for retaining compounds of interest, followed by selective elution. 
The aim of SPE is to isolate the relevant compounds from a sample matrix and to 
concentrate them. SPE is a physical extraction process that involves a solid phase 
and liquid phase [156]. The most widely used SPE materials are silica or bonded 
silica gel, in which the end-standing silanol groups have been derivated with an 
organic moieties that may consist of alkyl chains with or without a variety of 
functional groups, such as -OH, -C6H6, -NH2, -eN, -S03H, and -COOH [157]. 
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The extraction and elution of the drug are interdependent on the drug of interest, the 
sorbent in the extraction column, and the solvent used in the elution step. The drug 
of interest interact chemically and/or physically, i.e. based on polarity or ion 
exchange, with both the sorbent and the solvent used to extract and elute the drug. 
Therefore optimising the chemical and physical properties of the functional groups 
of the analyte (drug) during the solid-phase extraction is essential to enhance 
efficient separation [151]. Each step of the extraction procedure must be optimised 
carefully. 
Among the factors that may affect the behaviour of the relevant drugs during the 
extraction procedure include the selection of a suitable sorbent, the pH of the 
sample and the extraction system, the clean-up step, the properties and volume of 
the eluent, and the flow rate of the sample and the eluent passing through column 
[157]. 
The choice of sorbents is often based on how optimally it can extract the compound 
of interest by retaining the compound and allowing the impurities to pass through 
the column, by concentrating the retained compound after passing large sample 
volumes through the column, or by retaining and thus removing interfering 
impurities from the sample matrix. 
4.2.2. Bonded-phase partition chromatography (BPC) 
The sorbent in BPC is covalently bonded to a rigid silica gel support, and that allow 
it to be used with either negative or positive pressure. The resin will neither swell 
nor shrink; thus, reequilibration does not enter into consideration, hence widely 
varying pH will not destroy the resin in the short time it takes to perform an 
extraction. The result of these combined advantages is an extremely versatile and 
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powerful sample preparation technique [151]. Bonded-phase partition 
chromatography columns are classified as: 
4.2.2.1. Normal phase (Polar): 
These are used for the extraction of polar or hydrogen bonding compounds from a 
nonpolar, nonaqueous matrix. Here, the polar groups present on both the bonded 
phase sorbent and the drug sample are partitioned [158]. For maximum extraction 
efficiency, high solvent polarity and high solubility of the analyte must be 
considered [151]. 
Normal phase sorbents are not usually used for extraction of aqueous solutions, 
which results in few applications with regardto aqueous drug matrices. 
4.2.2.2. Reversed Phase (Nonpolar): 
Nonpolar columns extract nonpolar compounds from polar sample matrix. Here the 
extraction mechanism is based on retention of the compound of interest by 
hydrophobic interaction with the column sorbent [156, 158, 159]. When eluting 
nonpolar compounds from a sample solution, a combination of both low solvent 
polarity and high solvent solubility of the drug of interest is of optimal 
consideration [151]. 
Reversed phase columns are versatile and are used for almost all classes of drugs of 
abuse. They only require a small amount of organic solvent as an eluent. 
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4.2.2.3. Ion Exchange: 
The ionic character of the drug, which is always the opposite of the ionic charge of 
the functional groups of the resin, is the force behind binding the drug to an ion 
exchange column resin. Ion exchange chromatography SPE columns are classified 
as: 
• Negatively charged groups (anionic): Anion resins are used to extract analytes 
present in the sample matrix in an anionic form . 
• Positively charged groups (cationic): Cation resins are usually employed in the 
extraction of analytes present in the sample matrix in cationic form. 
These groups can be cationic or anionic depending on the pH of the solvent 
surrounding them. Hence for good retention of an isolate on a sorbent, two 
conditions must be met [156]: 
• The pH of the matrix/solvent must be at values that allow for both isolate and 
sorbent to be charged . 
• High concentrations of strongly competing ionic species of the same charge as the 
isolate must not be present in the matrix/solvent. 
A solid-phase extraction procedure usually involves five main steps: column pre-
conditioning, sample application, column wash, column drying (if necessary), and 
drug elution. 
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4.2.3. Extraction Procedure 
4.2.3.1. Column Preconditioning (Solvation) 
The column has to be pre-treated with suitable solvent(s) for high reproducible 
recovery. The dried sorbents in bonded silica gel extraction columns are packed, 
hence the active sites are not available to interact with analyts and proper column 
conditioning is required before sample application. The sorbent must be 
preconditioned with suitable organic solvent, for example, methanol followed by 
water or buffer wash (non-polar and multiple interaction phases) or hexane (polar 
phase). The organic solvent is used in this step to solvate the bonded functional 
groups for opening the hydrocarbon chains, and to remove organic residues from 
the sorbent that may interact with the analye or interfere in the detection stage. 
Water or buffer, of which the pH, ionic strength, and polarity have been adjusted, is 
added afterwards to remove excess organic solvent to prepare the SPE column to 
receive an aqueous sample [157]. The main task at this stage is to keep the sorbent 
solvated before sample application. 
4.2.3.2. Sample Application 
Once the column is preconditioned, the sample is transferred onto the SPE column, 
and drawn it by applying a gentle vacuum. It is important to note here that a slow 
flow rate is necessary to ensure excellent retention of the analytes [160, 161]. 
4.2.3.3. Column Wash 
Retention of relevant compounds is usually accompanied by retention of other 
endogenous components. Thus a column wash with water or an appropriate solvent 
is required to remove any interfering substances. Careful selection of the wash 
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solvent is required in order to avoid any substantial loss of relevant compounds 
during the wash process. Finding a solvent with the ability to clean the column 
without losses of the relevant compounds is difficult. Therefore a compromise must 
be reached between acceptable recoveries of a wide range of different substances 
and adequate removal of matrix compounds. The first step should be dedicated to 
an acceptable recovery of the relevant substances followed by cleaning up 
optimising step [157]. Sometimes pH alteration of the extraction system is 
introduced at this stage to allow for selective elution as the behaviour of most of 
drugs is dependent on the pKa and the pH of the extraction system [160-162]. 
4.2.3.4. Column Drying 
Column drying is not usually necessary when water miscible organic solvent or 
buffer solution is used as an eluent and the final analysis is carried out on reversed-
phase HPLC. But if a water immiscible solvent is used as an eluent and the final 
analysis is to be performed with GC, then a drying step is necessary to remove all 
traces of water from the SPE column prior to the elution step. If water present it 
may cause difficulties with sample elution, further steps such as derivatisation or 
damage the GC column. There are two ways to remove residual water, either by 
applying airflow through the sorbent or by adding a suitable organic solvent, or both 
[160]. 
4.2.3.5. Elution 01 relevant substances 
Performing elution of the relevant substances is completed by passing a suitable 
eluent strong enough to ensure complete elution of the drugs through the SPE 
column. The eluent should be selective so that the interfering substances are 
retained on the column. 
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There are certain factors to be considered before eluent selection, such as, the 
polarity (P'), the solvent selectivity, and the eluotropic strength (E) of the elution 
solvent [163, 164]. Solvent strength and solvent selectivity are not the same. Snyder 
[163] stated that solvent strength is its polarity or ability to preferentially dissolve 
more polar compounds, while the solvent selectivity is its ability to selectively 
dissolve a particular compound when polarities of compounds are similar. 
According to Snyder, solvents are classified into eight selectivity groups (I-VIII) 
depending on their proton donor, proton acceptor, and dipole interactor 
characteristics. However, Chen et al [160] proved that the P' value is not too 
critical. Thus when selecting the best eluent system that have similar P' values but 
with different selectivities, both P' and the selectivity of the solvent should be 
considered. For example, ethyl acetate and isorpropanol have the same P' value but 
belong to different selectivity groups. 
Among other factors that have noticeable effect on the process of developing an 
extraction procedure are: 
Eluent Volume: It is important to realise that using large volumes of the eluent will 
cause dilution of the extract [165]. Increasing the eluent volume will also result in 
prolonged extraction period, causing loss of the more volatile drugs and elute more 
interfering substances [160]. 
Flow Rate of the Eluent: In order to allow an adequate interaction of the relevant 
substances with the stationary phase and mobile phase, the flow rate should be 
controlled. Slow flow rates (0.5-2 ml/min) have been tested and showed improved 
recovery [149, 162, 166-169]. 
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Solid-phase extraction (SPE) has now taken its place in the analytical laboratory as 
a fast, convenient and efficient method to prepare a clean sample for 
chromatography and spectroscopy. Although the cartridge has been traditionally the 
main format, which was used for SPE sample preparation, recently, new formats 
have proved to be more suited to the type of sample being prepared. There are four 
major extraction techniques used prior to analysis presently: Soxhlet (SOX), liquid-
lquid (L-L) , solid phase (SPE), and supercritical fluid (SFE). Of the analysts 
performing sample preparation, 46% use L-L, 36.4% use SPE, 23% use SOX, and 
3% use SFE [154]. This was a result of a survey conducted in 1991. Since then, 
conventional and automated solid phase extraction have been used on wider range 
of applications. 
4.3. EXPERIMENT AL 
4.3.1. Chemicals 
1. Column conditioning solvents: methanol & water both HPLC grade. 
2. Buffer solution: Phosphate buffer at pH 4-10 
3. Eluting solvents: Isopropanol, ethyl acetate, isooctane, hexane, and 
dichloromethane. 
4.3.2. Apparatus 
1. Solid phase extraction columns: 
a. Bond Elute: Certify (130 and 300 mg), CI8 (200 and 500 mg) 
b. Isolute: C 18 (200 and 500 mg), C8 (200 and 500 mg) 
2. Vacume Manifold: VAC-ELUT (Varian). 
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4.3.3. Optimising SPE Procedure 
The optimisation of the SPE procedure was carried out in three main steps 
1. Examination of the best extraction pH 
2. Evaluation of eluting solvents used for extracting impurities 
3. Assessment of different SPE columns 
4.3.3.1. Examination of the best extraction pH 
One ml of phosphate buffer was added to 50 mg of fine homogeneous ecstasy 
powder, the solution was then mixed and shaken for 30 min, centrifuged for 5 min. 
and the supernatant was taken off. A SPE column (Bond Elut Certify 130 mg) was 
conditioned with 10 ml of deionised water (to remove water-soluble impurities due 
to manufacture of the cartridge), 10 ml methanol (to solvate the column and remove 
other impurities), and 10 ml de ionised water (to remove excess solvation solvent). 
The sample (supernatant) was then applied to the column at 1-2 mVmin. The 
column was then washed with 10 ml deionised water (to remove sugars and other 
unwanted water-soluble compounds) and dried under maximum vacuum (15 psi) 
for 5 min. The sample was subsequently washed with 0.7 ml isopropanol (to 
remove any remaining water and reduce lipophilic bonding between the analytes 
and the sorbent surface) followed by 1 ml ethyl acetate with 2 % ammonia (to elute 
freed analytes by eliminating ion-exchange interactions). The collected sample was 
evaporated in a nitrogen stream to about 100 f.ll. 1 f.ll of the sample was injected in 
the GC-FID. The pH of the phosphate buffer ranged from 5 to 10. The optimum pH 
was determined using visual comparison of the chromatograms. 
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4.3.3.2. Evaluation of eluting solvents for the one with most impurities extracted 
The same extraction procedure was repeated under the optimum pH determined 
above using four different eluting solvents, ethyl acetate, dichloromethane, hexane, 
and isooctane. An internal standard, triethylamine, was added before sample 
introduction to the gas chromatograph. The relative peak areas were calculated and 
bar charts were drawn for the main peaks to determine the best eluting solvent. 
4.3.3.3. Assessment of different SPE columns 
Once the optimum extraction pH and the best eluting solvent were determined an 
assessment of different SPE columns using the same extraction procedure as above 
was performed. The columns used for the assessment study were, Bond Elut CI8 
200 mg, C 18 500mg, Certify 300mg, Certify I30mg and Isolute C8 200mg, C8 
500mg, CI8 200mg, CI8 500mg. An internal standard, triethylamine, was added 
before sample introduction to the gas chromatograph. The relative peak areas were 
calculated and a bar chart was drawn for the main peaks to determine the 
performance of each type of SPE column. Throughout all the extraction procedures 
performed above, the same ecstasy sample was used to assure that any variations 
were due to different extraction procedure parameters not due to different samples. 
4.3.3.4. Blank Extracts 
The same extraction procedure was used with blank extracts to ensure impurities 
other than those present in the tablets were absent. 
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4.3.3.5. Stability of Extracts during Storage 
Extracts were stored at 4°C in the dark, and were re-analyzed over a period of 4 
weeks to check their stability 
4.3.3.6. Application to Real Samples 
Three ecstasy samples seized from different individuals at different locations were 
analysed with optimised conditions. 
4.3.3.7. Gas Chromatography 
The GC was an Hewlett-Packard 5890series II with flame ionization detector. One 
J.lI of sample was injected with an injection port temperature of 280°C. Gas 
chromatography was carried out using a fused silica capillary column (HP5, 30 m x 
0.32 mm i.d., 0.25 !lm film thickness) programmed from an initial temperature of 
80°C (1 min) at 35°C/min to 180°C (held for 18 min) then at 50°C/min to 300°C 
(held for 2 min). 
4.3.4. Solid phase extraction (SPE) Vs Liquid-liquid Extraction (LLE) 
A comparison of SPE and LLE to evaluate and justify the use of SPE as an 
alternative extraction procedure to LLE. Ten portions, 50 mg each, of a ground and 
homogenised ecstasy sample, were separated into two groups each consisting of 
five portions. One group was subjected to LLE while the other to SPE. Both groups 
were analysed by GC-FID. 
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4.3.4.1. Solid phase extraction (SPE) 
SPE procedures were carried out using Varian Bond Elute C 18 (200 mg) columns. 
The tablets were crushed and 50 mg of the homogeneous powder were dissolved in 
Iml phosphate buffer at pH 9. The solution was then mixed and shaken for 30 min., 
centrifuged for 5 min. and the supernatant was removed. The SPE column was 
conditioned with 10 ml of deionised water (to remove water-soluble impurities due 
to manufacture of the cartridge), 10 ml methanol (to solvate the column and remove 
other impurities), and 10 ml deionised water (to remove excess solvation solvent). 
The sample was then applied to the column at 1-2 mllmin. The column was then 
washed with 10 ml deionised water (to remove sugars and other unwanted water-
soluble compounds) and dried under maximum vacuum (15 psi) for 5 min. The 
sample was subsequently washed with 0.7 ml isopropanol (to remove any 
remaining water and reduce lipophilic bonding between the analytes and the sorbent 
surface) followed by 1 ml ethyl acetate with 2 % ammonia (to elute freed analytes 
by eliminating ion-exchange interactions). The collected sample was evaporated in 
a nitrogen stream to about 100 Ill. This is the developed SPE procedure from 
section 4.3.3. 
4.3.4.2. Liquid-liquid Extraction (LLE) 
A volume of Iml of phosphate buffer at pH 9 was added to 50 mg of the same 
homogeneous powder used for the SPE procedure. The solution was then mixed for 
1 min. and shaken for 30 min. Another volume of Iml of ethyl acetate was added to 
the solution and shaken again for 30 min. The sample was then centrifuged for 5 
min. at 3000 rpm and the organic layer was removed and evaporated in a nitrogen 
stream to about 100 Ill. At this stage IOOIlI of triethylamine, internal standard, was 
added. Only 1 III of the sample was injected in the GC-FID. 
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4.3.4.3 Blank Extracts 
Two blank solutions were extracted by LLE and SPE using the same buffer and 
same solvent used throughout the whole work to insure that impurities other than 
those present in ecstasy samples are not present. 
4.3.4.4. Application to Real Samples 
Twelve different samples of seized ecstasy tablets were analysed using solid phase 
extraction, GC-FID. The extraction procedure was similar to the SPE procedure 
mentioned above as were the GC-FID. 
4.4. RESULTS AND DISCUSSION 
The optimisation procedure carried out on a sequence to allow the use of the 
optimum determined parameter for the next step of the optimisation procedure. 
4.4.1. Examination of the best extraction pH 
Six different pH values (5-10) were examined using the same eluting solvent (ethyl 
acetate) and the same SPE columns (Bond Elut Certify 130mg). The SPE 
procedures were run for all pH range on portions of the same homogeneous ecstasy 
powder using the same. Figure 4.1 a and 4.1 b illustrate the superiority of extracting 
with pH 9 over other pH values. 
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Figure 4.1a. Impurity profile of sample 001 at pH 5, 6, and 7 respectively. 
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Figure 4.1 b. Impurity profile of sample 001 at pH 8, 9, and 10 respectively. 
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The optimum pH at 9 yielded better impurity profile with a greater number of 
impurity peaks present allowing for a better chemical signature comparison. 
4.4.2. Evaluation of eluting solvents for the one with most impurities 
extracted 
In the evaluation of the eluting solvents procedure four solvents were used; ethyl 
acetate, hexane, dichloromethane and isooctane using the optimised pH 9 and Bond 
Elut certify 130 mg. Ethyl acetate yielded the best impurity profile providing 
impurities with higher relative peak areas as illustrated in figure 4.2. Although all 
four eluting solvents examined yielded acceptable profiles, ethyl acetate produced a 
profile for all the ten studied impurity peaks with reasonable relative peak area. 
Therefore ethyl acetate was the solvent of choice for the elution step. 
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Figure 4.2. Bar charts demonstrate the extraction power of different elution solvents, 
mean relative peak areas (y-axis) Vs peak number (x-axis). 
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4.4.3. Assessment of different SPE columns 
Eight SPE colwnns from two manufacturers (Varian and International Sorbent 
Technology, 1ST) were evaluated. All SPE columns were examined using the 
optimised pH 9 and the optimised eluting solvent, ethyl acetate. After evaluation of 
the determined impurity profiles, Varian C 18 (200mg) provided the best impurity 
profile with the highest relative peaks areas as it is illustrated in figures 4.3, 4.4a 
and 4.4b. 
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4.4.4. Blank Extracts 
A blank sample consisting of only a buffer solution at pH 9 was extracted with the 
optimised eluting solvent, ethyl acetate and by the optimised SPE column, Varian 
Bond Elut CI8 200mg. This step was necessary to be certain that all the peaks used 
for the evaluation were not generated from any source other than the homogenised 
ecstasy powder. Figure 4.5 demonstrates a chromatogram of a blank sample 
extracted with the conditions mentioned above. 
2.204 
2.C)c4 
I. .... 
1.6<:4 
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Figure 4.5. Chromatogram of a blank extracted with the optimised parameters 
4.4.5. Stability of Extracts during Storage 
A demonstration of the stability of extracts during storage was examined for an 
ecstasy sample extracted with optimised procedure. The extract was analysed by 
GC-FID four times over a period of four weeks, meanwhile stored in the dark at 
4°C for the whole period and was taken out briefly for the analysis. Figure 4.6 
illustrates the stability study of the extracts profile over the four weeks period. 
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Figure 4.6. Impurity profiles of ecstasy sample demonstrating stability of extracts over a 
period of four weeks 
After four weeks of storage of extracts in the dark at 4°C, the impurity profiles showed no 
major changes and were still valuable for comparison purposes. 
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4.4.6. Liquid-liquid Extraction (LLE) Vs Solid Phase Extraction (SPE) 
Five portion of the same ecstasy sample extracted by LLE and analysed by GC-
FID. The principal peaks of chromatograms representing impurities of each portion 
were numbered and the means of their relative peak areas were calculated. The 
same procedure was performed for the other five portions extracted by PE. 
Extraction Peak No. n Mean S.D. 
Method 
SPE 1 5 1.617 0.842 
2 5 3.276 0.222 
7 5 0.5178 0.0396 
LLE 1 5 0.628 0.140 
2 5 0.968 0.110 
7 5 0.4016 0.0398 
Table 4.1. Mean and standard deviation of the relative peak areas of peaks 1, 2, and 
7. 
To evaluate the data collected from the various chromatograms of ecstasy sample 
extracted by SPE and LLE, statistical analysis was performed to compare the means 
of important impurity peaks present in the chromatograms. The means of seven 
major impurity peaks were used for the statistical analysis and three of those means 
(peak number 1, 2, and 7) as illustrated in table 4.1 were further analysed by 
running a significantal test. The two-sample t-test was used to assess if the 
differences in the means of the relative peak areas of the selected peaks were 
significantly different for each extraction method. Comparison was performed for 
the means of relative peak areas of peaks number 1, 2, and 7 of each extraction 
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method and the p value was calculated by the use of computer software (Minitab). 
The p value of each t-test as shown in table 4.2 proved that there is significant 
difference between the evaluated means. Since the means of relative peak area for 
samples extracted by SPE were larger than those extracted by LLE and that the p 
value showed significant difference in those means it is safe to conclude that SPE 
provided a better extraction yield of impurities in ecstasy samples. 
Two SAMPLE T -TEST FOR PEAK 1 
95% C.l. for LLE 1 - SPE 1: (-1.859, -0.12) 
T-Test LLE 1 = SPE 1 ( not =): T= -2.57 
P=0.030 DF= 9 
Two sample t-test for peak 2 
95% C.I. for LLE 2 - SPE 2: (-2.564, -2.053) 
T-Test LLE2 = SPE2 ( not =) : T= -20.82 
P=0.001 DF= 9 
Two sample t-test/or peak 7 
95% C.l. for LLE 7 - SPE 7: (-0.176, -0.057) 
T-Test LLE 7 = SPE 7 ( not =) : T= -4.63 
P=0.0025 DF= 9 
Table 4.2. Two sample t-test results of peaks I, 2, and 7 for both extraction methods 
SPEand LLE 
Another illustration of the differences in the mean of relative peak area of peaks 1, 2, and 
7 is shown in figure 4.7 where SPE yielded better peak recovery than LLE. 
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Figure 4.7. Comparison of means of relative peak areas for three different peaks of an 
ecstasy sample extracted by LLE and SPE. 
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4.4.7. Blank Extraction by LLE and SPE 
Blank extracts showed no major peaks especially at the retention time as the ecstasy 
impurity peaks where present. Figure 4.8 demonstrates chromatograms of two blank 
samples extracted by LLE and SPE. 
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Figure 4.8. Chromatograms of blank sample extracted by LLE and SPE. 
4.4.8. Applications to seized samples 
The magnitude of inter- and intra-batch variation of impurity profiles governs the 
establishment of a "common source". Intra-batch variation should be less than inter 
batch-variation since samples belonging to the same batch expected to show more 
similarities than samples belonging to different batches. 
4.4.8.1 Comparison of different seizures (Inter-sample variation) 
Ecstasy samples from 11 different seizures (packages) were extracted by solid 
phase extraction and analysed by GC-FID for the purpose of establishing 
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commonality. Figure 4.9 shows a comparison of impurity profiles of three ecstasy 
samples from three different seizures. 
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Figure 4.9. Impurity profiles of three different samples 002, 006, and 008 from three 
different seizures 
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The above impurity profiles allowed for visual comparison of three different ecstasy 
samples. It is clear that they contain great variations and consequently do not belong 
to a common batch (source). 
4.4.8.2 Comparison of tablets from same seizure (Intra-sample variation) 
Impurity profiles of two randomly chosen ecstasy tablets from the same seizure 
(package) were obtained using solid phase extraction and GC-FID. The generated 
impurity profiles showed similarities indicating that both samples belong to the 
same batch. Figure 4.10 demonstrate an overlay comparison of their impurity 
profiles showing little variation. 
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Figure 4.10. Impurity profiles of two samples from the same seizures 
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The advantages of using solid phase extraction for profiling of illicit drugs are 
numerous but most among those are efficiency, absence of contamination of phases 
and absence of emulsions problem, as found with LLE, due to the presence of fatty 
acids in ecstasy tablets. Secondly, profiling can be very difficult with a samples of 
high purity since the impurity profile is dependent on impurity abundance in the 
sample. An excellent extraction of impurities in high purity drug exhibits by LLE 
requires repeated extractions and the use of large volume of solvents, which can 
cause loss of analytes and consequently poor impurity profiles. SPE can provide 
excellent impurity profiles with superior selectivity, high recovery and reduced 
organic solvent consumption. 
4.5. FUTURE WORK 
Finally, the possibility of automating the extraction procedure which is more easily 
automated with SPE than with LLE. The automated SPE procedure will provide an 
unattended extraction saving precious analytical time and manpower, establishing 
more consistency and repeatability in the analysis, and allowing for a total 
automated procedure including extraction, chromatography, and data and statistical 
analysis. 
4.6. CONCLUSION 
The optimisation of the solid phase extraction (SPE) procedure for the purpose of 
profiling impurities found in ecstasy tablets manufactured in clandestine 
laboratories was examined. The determined optimum parameters for the SPE 
procedure were as follows: 
Characterisation and Profiling of Ecstasy Tablets Page 92 
1. Buffers with pH 9 were found to be the optimum for extracting impurities of ecstasy 
tablets. 
2. The eluting solvent with most impurities extracted was ethyl acetate. 
3. Among all the eight SPE columns evaluated, Varian Bond Elut CI8 200mg produced 
the best impurity profile allowing for easy comparison of profiles of real samples. 
Solid phase extraction of impurities in ecstasy tablets proved to be more efficient 
than the traditional liquid-liquid extraction. SPE provided impurity peaks with 
higher intensities than did LLE and SPE has a shorter extraction time. Street 
samples of ecstasy were analysed for profiling purposes using SPE procedure. 
Samples from different seizures (packages) showed little variations and great 
similarities indicating common batch origin while those from different packages 
showed great variations indicating different batch origin. 
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5. ECSTASY PROFILING BY INFRARED 
SPECTROSCOPY 
5.1. INTRODUCTION 
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In previous chapters, chromatographic instrumentation was used to perform 
impurity profiling of ecstasy tablets, in particular gas chromatography with flame 
ionisation detection. Chromatographic methods are powerful tools for comparing 
drug seizures, but they do have their inherent limitations so a combination of at 
least two methods is more acceptable. Infrared spectroscopy and in particular 
fourier transform infrared, FTIR, can serve as another tool for comparing drug 
seizures. Each exhibit has its own characteristic spectrum, and comparison between 
the different spectra gives a gross estimate of the similarity or dissimilarity between 
the different exhibits. FTIR has some discriminating capability to classify powders 
into a large number of groups, and consequently can be used for gross comparison 
of ecstasy exhibits. 
FTIR has some advantages over chromatographic methods such as reduced sample 
handling, faster analysis time, no need for impurities extraction and concentration 
procedure, and lack of volatility, solubility, thermal stability or column limitation. 
However, it has some major disadvantages including low sensitivity and inability to 
detect trace components. 
This chapter deals with the subject of ecstasy profiling (that is, attempt to carry out 
gross comparisons between ecstasy seizures) through the use of FTIR as a screening 
tool in drug profiling procedures. 
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5.2. FOURIER TRANSFORM INFRARED, FTIR 
In a dispersive instrument a dispersing element, such as a grating or prism, produces 
a narrow band of infrared wavelengths. The sample absorption occurring for each of 
these bands is compared with that occurring for a reference beam, by continuously 
varying the wavelength of the chosen band, one obtains a spectrum. With an FTIR, 
all of the radiation from the source is sampled [170]. Based on an interferogram that 
is produced, a mathematical dispersion is computed, which produces a spectrum. 
Fourier transform infrared instruments measure light absorbed or emitted from a 
sample. The measurements provide valuable chemical composition information. 
Fourier transform infrared spectrometers record the interaction of IR radiation with 
experimental samples, measuring the frequencies at which the sample absorbs the 
radiation and the intensities of the absorption. Determining these frequencies allows 
identification of the samples chemical make up, since chemical function groups are 
known to absorb light at specific frequencies [171]. 
Adjustable 
torold.1 
window 
Sample ere. 
Figure 5.1. A single-beam FTIR spectrometer [170] 
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The key components of a FTIR system are the source, the interferometer, and the 
detector (Figure 5.1). The interferometer provides a means for the spectrometer to 
measure all optical frequencies simultaneously. The interferometer modulates the 
intensity of individual frequencies of radiation before the detector picks up the 
signal. The basic components of an interferometer include a beam splitter, a fixed 
mirror and a moveable mirror (figure 5.2). Half of the infrared light is reflected 
from the beam splitter to the fixed mirror and back to the detector, while the other 
half of the light is passed through to the moveable mirror, and then back to the 
beam splitter, where the beam is again split, and half of the light from the reflected 
beam is passed to the detector. Using a polychromatic light source, the moveable 
mirror is moved so that the two light beams interact constructively. The detector 
records the sum of the cosine waves of the polychromatic light, and hence data for 
all wavelengths to be considered is collected at once, improving the speed of the 
instrument [171, 172]. 
Fixed mirror 
0 ~ I Moveable mirror 
Beam splitter 
- Sample 
Detector 
Figure 5.2. An interferometer [173] 
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The product of an interferomete (scan) is called an interferogram, which is a plot of 
intensity versus mirror position. Using a mathematical process called Fourier 
Transform (FT), the system computer converts the interferogram into a spectrum. 
FTIR instruments have many advantages over the conventional dispersive 
instruments such as; quick scanning time, higher throughput energy since FTIR 
instruments have no slits to isolate a band of wavelengths as in dispersive 
instruments, better signal to noise ratio which result in improved spectrum quality, 
possibility of mathematical manipulation of the data, and the possible coupling of 
FTIR to microscopy and chromatography [173]. 
5.3. SAMPLING TECHNIQUES 
There are various ways of presenting samples for FTIR analysis: as gaseous, liquid 
and solid sampling. 
5.3.1. Gaseous Sample 
Because of the low volatility of drugs of abuse, measurements of the gaseous 
infrared spectrum of drug samples is of little importance to the forensic scientist. 
There are only few compounds such as nitrous oxide that are suitable for gaseous 
phase FTIR spectroscopy 
5.3.2. Liquid Sample 
Liquids are analysed in pure form or in solutions. Analysis of liquids may be the 
easiest to handle since they may be poured into cells made of alkali metal halides 
such as sodium chloride or potassium bromide and the IR spectrum determined 
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directly. However, cell etching occurs with time because of water content in 
samples and interference patterns becomes more noisy. 
5.3.3. Solid Sample 
Three main methods are used for solid samples, the nujol mulls, thin films and 
pressed pellets. 
5.3.3.1. Pressed Pellets 
The most commonly used, but basic, method of analysing solid samples is the 
traditional KBr disk. Also known generically as the halide disc technique, the 
system was developed over 40 years ago and has remained unchanged since. The 
sample is first ground into a fine powder. It is then mixed with KBr and the 
grinding process continued. A mortar and pestle is normally used to grind the 
materials, but in laboratories where many discs are made each day an electrical mill 
is used. A capsule is used to contain the sample during the milling process. 
Materials of capsule construction include polystyrene, stainless steel and agate. The 
finely ground materials are then removed from the mill and placed in a KBr die to 
complete the process. Die sizes range from 1 mm diameter for micro samples up to 
the traditional 13mm diameter disc. Although the designs of dies differ widely, their 
basic function is to sandwich the mixture between two polished surfaces and press 
the KBr and sample in to a disc. High pressure is applied, either by means of levers 
or a hydraulic press, to coalesce the sample into a transparent or semi-transparent 
disc. A vacuum line, connected to the die, removes entrained air and, to a limited 
extent, entrained moisture. As entrained moisture can cause the finished disk to be 
opaque the KBr powder should be kept dry by means of a descicator or a heated 
oven. Moist samples are not suited to this technique, as they will cloud the disc. 
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Such samples should be dried before analysis. The prepared disc is mounted in the 
beam of the spectrometer, so that it may be analysed. Careful attention to the 
sampling methods, disk making techniques and water content of the sample and 
KBr powder is still considered to be at the heart of making a quality disc. 
5.3.3.2. Nujol Mulls 
The sample is usually ground to a fine paste in a liquid hydrocarbon such as nujol. 
This method is rapid and easy, but it is unsuitable for quantitative analysis because 
it is difficult to prepare mulls with accurately known concentrations of analyte. The 
other main disadvantage of this method is that it requires a large amount of sample. 
5.3.3.3. Thin Films 
Thin films are used to obtain a spectrum free from a dispersing medium. A small 
amount of the drug is dissolved in a volatile, water free solvent and a portion of this 
solution is then placed on a salt plate where the solvent left to evaporate. The 
compound is then analysed on FTIR as a thin film. 
5.4. DATA ANALYSIS 
The use of computers in data collection and manipulation has led to an increase in 
IR spectral libraries. Collection of data in digital form allows a spectrum to be 
manipulated, stored and retrieved. Most manufacturers of infrared instruments now 
offer computer search systems to assist the analyst in identifying compounds from 
stored infrared spectral data. The position and relative magnitude of peaks in the 
spectrum of the analyte are determined and stored in memory to give a peak profile, 
which can then be compared with profiles of pure compounds stored. The computer 
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then matches profiles and prints a list of compounds having spectra similar to that 
of the analyte. 
A number of factors that effect data interpretation should be taken into account 
when performing a computerised library search. Has the spectrum under 
consideration been prepared in the same conditions as the library spectrum? If not 
then small shifts in wavenumbers at which absorbances occur may happen [173]. A 
good solution to this problem is to create an in-house library of spectra of most 
drugs encountered by the analyst under the same conditions. Another factor is that 
databases and libraries are only means of providing possibilities for the identity of 
the compound with a measure of degree of fit of the spectrum obtained with that in 
the library. Hence, While library searching allows the analyst to gain some idea of 
the identity of a drug, the spectrum should always be compared to that obtained for 
an authentic sample of the compound, obtained under identical conditions. 
5.5. APPLICATIONS 
Various applications of IR spectroscopy for drugs analysis are cited in the literature, 
from screening unknown exhibits for identification of controlled substances to 
comparison of different seizures for intelligence purposes. 
5.5.1. Samples Screening and Qualitative Analysis 
Infrared spectroscopy can be valuable tool for screening samples for the purpose of 
identifying a controled substance. Screening with FTIR in particular is convenient 
because of both its speed and its ability to use accessories requiring minimal sample 
preparation. Many illicit drugs clandestinely manufactured often contain adulterants 
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and diluents such as sugars, starch or inorganic substances (for example, talc or 
sodium bicarbonate). Conventional drugs screening methods, such as colour tests, 
gas chromatography, or ultraviolet spectroscopy, do not normally detect these 
substances. Infrared spectroscopy screening is possible for these substances because 
they have strong absorption in the infrared region. 
5.5.2. Comparisons of Drug Seizures 
As mentioned at the beginning of this chapter, infrared spectroscopy can be used as 
an add-on tool for the characterisation and comparison of seized drugs for 
intelligence purposes by direct/rigorous comparison of two exhibits or classifying 
seizures into groups by gross comparison. 
Many workers reported the use of infrared spectroscopy for 1) identification of 
impurities in seized drugs to establish the method of synthesis [53, 174], 2) direct 
comparison of samples [36], and 3) identification of major excipients in illicit drugs 
for comparative studies [144, 145]. 
5.6. EXPERIMENTAL 
5.6.1. Materials 
Forty-seven ecstasy samples from twenty-four seizures were used in the 
experiment. The Forensic Science Service, Metropolitan laboratory, London, 
provided street samples of ecstasy tablets. Standards of MDMA, lactose, glucose 
and caffeine were obtained from Sigma. 
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5.6.2. Sample Preparation and Instrumental Analysis 
Samples were prepared using KBr disks. Around 1 mg of sample was ground by 
pestle and mortar into a fine powder. Then about 300 mg of oven dried KBr were 
added and ground again to a fine homogeneous powder. The finely ground sample 
was then removed and placed in a 13mm KBr die to sandwich the mixture between 
two polished surfaces and press the KBr and sample into a disc. High pressure 
(12000kg) was then applied by means of a lever to coalesce the sample into a 
transparent or semi-transparent disc. Vacuum was applied to the die to remove 
entrained air, and to a limited extent, entrained moisture. As entrained moisture can 
cause the finished disc to be opaque. The prepared disc was then mounted in the 
beam of the spectrometer for analysis. Infrared spectra were obtained using a Jasco 
FTIR-410 Spectrometer (Jasco UK Ltd., Essex, UK). 
5.6.3. Spectra Comparison 
An in-house library was created which contained spectra for standards and 47 
ecstasy samples. Once spectra for standards and all 47 ecstasy samples were 
obtained, comparisons of spectra using a library search facility from a commercially 
available spectral program called Spectra Manager SSP-400 search program (Jasco 
UK Ltd., Essex, UK) were performed for the purpose of establishing similarity or 
dissimilarity between the different samples. The library search was done using an 
algorithm for correlation coefficient for comparison purposes. This method 
conducts a search by comparing the spectrum waveform of an unknown sample 
with the spectral waveforms of library spectra. The library search provides best fits 
or closest matches from the library spectra to the unknown spectrum. A higher 
number means a closer match (1 being the highest and 0 being the lowest). The 
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comparison procedure was based on two main elements, 1) the library search results 
(best fit) and the visual comparison of spectra using an overlay diagram. 
5.6.4. Repeatability of Analysis 
To test the repeatability of spectra a single sample was analysed as above ten times 
using the same procedure and parameters including sample preparation as a disc 
and analysis on FTIR. Statistical analysis was then performed to calculate relative 
standard deviation (RSD). 
5.6.5. Comparison of tablets from different seizures 
Tablets from different seizures chosen randomly were analysed for the purpose of 
establishing common source. Each tablet was ground, extracted, and analysed 
separately to avoid cross contamination. The result spectra were compared by the 
use of library search facilities. 
5.7. RESULTS AND DISCUSSION 
The aim of comparative analysis is the comparison of confiscated drugs for 
investigative purposes and court testimony. Drug intelligence involves two main 
streams with regard to comparative analysis or drug profiling. The first includes 
court cases such as sample/sample comparison and relating a user to a dealer. The 
second task for drug intelligence involves establishing relationships between 
seizures and providing information on the networking of samples, which maybe of 
use in investigating major trafficking operations. In such operations the laboratory 
may have to analyse many samples. FTIR analysis can be utilised for such 
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operations as an elimination tool because of its sheer simplicity and short analysis 
time. 
5.7.1. Repeatability of Analysis 
Repeatability is a vital factor in drug profiling procedures since little variations in 
data (spectra or chromatograms) can effect the interpretation of the comparison 
process. After analysis of sample number (MO 1) for ten times, reproducible spectra 
were obtained and the calculation of percentage relative standard deviation (R D) 
showed excellent repeatability of results. The procedure included running a library 
search on ten different spectra of sample (MO 1) and using the fit factors (library 
scores) from the search results to calculate percentage RSD. Table 1 illustrates the 
statistical results for the repeatability study. 
Column Statistics Results 
Mean 0.98 
- - - -
Standard Deviation .0098 
Minimum 0.974 
Maximum 1 
Count 10 
RSD (%) 1.003 
Table 5.1. Statistical results for the repeatability study. 
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5.7.2. Comparison of tablets from different seizures 
Comparison of spectra of samples from different seizures yielding different physical 
features such as colour and logos showed correlation of their spectra as seen in the 
example given in Figure 5.3 which shows an overlay comparison of two samples 
from different seizures. This technique can be used as a visual means of comparing 
spectra of similar tablets from different seizures or comparing two different exhibits 
to establish similarity or dissimilarity. 
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Figure 5.3. An overlay of spectra of sample 001 and sample 026 
1000 399.193 
The above method is useful when only small amounts of exhibits are compared. In 
the case of large amounts of seizures or in the case of building a database with 
many spectra included and samples to be related or grouped into smaller clusters, 
then use of computer software is faster and more useful. Visual comparison is still 
handy as a confirmation to the library search results and for court testimony 
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The above method is useful when only small numbers of samples are compared. In 
the case of large number of samples or in the case of building a database with many 
spectra included and samples to be related or grouped into smaller clusters, then use 
of computer software is faster and more useful. Visual comparison is still handy as 
a confirmation to the library search results and for court testimony presentation. In 
Table 5.2 an example is given of a library search result where a spectrum of an 
unknown (confiscated ecstasy tablet) was compared with a database of spectra of 
street ecstasy tablets. Figure 5.4 illustrates the library results in terms of spectra. 
Samples 013, 026 and the unknown showed similarities indicating their relation to a 
common batch These findings can be used positively to save time and laboratory 
work. The results of the FTIR analysis may be used to eliminate many samples 
before proceeding to more sensitive procedures such as chromatography. FTIR 
results can also provide a gross estimation of the different groups or profiles of 
drugs under investigation. 
Although FTIR technique is not sensitive enough to detect minute amounts of 
compounds such as manufacturing impurities, which are essential to the profiling 
process, it can still be a useful tool when its results are combined with other 
analytical procedures including physical analysis and microscopy and information 
from police investigations. 
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Order of Fit Score Sample Name 
1 0.977 013 
2 0.971 026 
3 0.900 032 
4 0.789 010 
5 0.769 014 
6 0.761 002 
Table 5.2. Library search results of sample 002 against library database for the 
closest match 
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Figure 5.4. Library search results of matching an ecstasy exhibit (sample 001) with 
a database of other ecstasy samples 
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5.S. CONCLUSION 
FTIR can be a very useful tool for comparative analysis of confiscated drugs for its 
sheer simplicity with regard to sample preparation and instrumental procedure, 
short analysis time and excellent repeatability of results. The library search facility 
provided a way to compare two samples and relate a sample to a group of sanlples 
from different seizures analysed previously. Comparative studies on confiscated 
ecstasy tablets through the use of FTIR when combined with a study of the physical 
features of tablets such as colour, size, logo, and microscopic analysis are possible 
and help provide information for the drug investigation process. 
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6. SYNTHESIS OF MDMA 
6.1. INTRODUCTION 
The various N-substituted derivatives of 3,4-methylenedioxyamphetamine, MDA 
have been popular drugs of abuse since the early eighties. The N-methyl derivative, 
3,4-methylenedioxymethylamphetamine (MDMA, Ecstasy, or XTC) is perhaps the 
most widely abused drug of this series. MDMA has been known and patented since 
1914. 
6.2. SYNTHETIC ROUTES 
Because there is no therapeutic application of MDMA its synthesis is carried out 
exclusively in clandestine laboratories. A variety of methods have been reported for 
the synthesis of MDMA [56]. 
There are five precursors that are most often used for the manufacture of MDMA, 
including safrole, isosafrole, piperonal, beta-nitroisosafrole, and piperonyl methyl 
ketone (PMK) or as it also called 3,4-methylenedioxy-phenyl-2-propanone (3,4-
MDP-2-P). The first three are available commercially but require a drug-purchasing 
license. However, safrole can be extracted from the sassafras plant native to the 
United States. Safrole is then easily isomerized into isosafrole when heated with 
NaOH or KOH. The isosafrole is then oxidised into PMK. Safrole and isosafrole 
can be used either directly via the bromopropane route to synthesise MDMA or 
used to prepare piperonylacetone which is not commercially available any more. 
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Piperonal in general is used in the preparation of beta-nitroisosafrole, which is also 
not available in the licit market. 
The most common routes for the production of MDMA are from the precursor 
MDP-2-P (PMK.) as seen in Figure 6.1. 
8cheme3 
( .... , 
Figure 6.1. Different routes for MDMA synthesis via PMK [56] 
Once the PMK is synthesised there are several synthetic routes which can be taken: 
1. Sodium Cyanoborohydride 
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2. Aluminum Amalgam 
3. Sodium Borohydride 
4. Raney Nickel Catalysis 
5. Leuckart Reaction via N-fonnyl-MDA 
6. Leuckart Reaction via N-methyl-N-fonnyl-MDA 
The sodium cyanoborohydride method is probably the one most attractive to clandestine 
chemists. It requires no knowledge of chemistry, has a wide applicability, offers little 
chance of failure, produces good yields, does not require expensive chemical apparatus or 
glassware and uses currently available and easily synthesised precursors. The aluminium 
amalgam synthesis is often used but has a slightly higher risk of failure and is not as 
versatile. The sodium borohydride requires harsher conditions for the chemicals (i.e. 
reflux) than sodium cyanoborohydride or aluminium amalgam and produces lower yields. 
The Raney Ni synthesis is more dangerous and requires special equipment to be done 
right (although this scheme is used in a significant number of clandestine labs). The 
Leukart reaction is a 2-step process with lower yields and requires chemical apparatus 
[56]. 
There are also other synthetic methods which proceed directly from safrole. The first 
method, bromination route, uses HBr to produce 3,4-methylenedioxyphenyl-2-
bromopropane which is then converted into MDA or MDMA. This route is attractive to 
clandestine laboratories for its sheer simplicity and that it requires no specialised 
chemical equipment or reagents at all. The second method is the nitropropane route, 
which uses piperonal to synthesise 3,4-methylenedioxyamphetamine, MDA. MDA is 
then converted to MDMA [175], which makes this method unlikely to be used by 
clandestine laboratory [56]. Figure 6.2 illustrates a summary of the different synthetic 
routes utilised in clandestine laboratories for manufacturing MDMA. 
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OIL OF SASSAFRAS ---. SAFROLE ---. ISOSAFROLE ---. 3,4-MDP-2-P 
(e"""Clion) 1 (isomerization) 
*6. Safrole + HBr 
7. Nitropropane route 
* Of interest to aspiring kitchen chemists 
* I. Sodium cyanoborohydride 
*2. Aluminium amalgam 
3. Sodium borohydride 
4. Raney Ni catalyst 
5. Leuckart reaction 
Figure 6.2. Summary of the different synthetic routes used to manufacture MDMA 
(J The sodium cyanoborohydride method is the most preferred method 
(J The aluminium amalgam route is as useful as cyanoborohydride, but may have a 
slightly higher risk of failure. 
(J The bromination route is attractive due to its sheer simplicity 
Schemes 1-4 use PMK as the starting precursor, which can be synthesised from Safrole or 
isosafrole. 
In this study only the reductive amination routes ( sodium cyanoborohydride and 
aluminium amalgam), the Leuckart reactoin, the bromopropene and the nitropropane 
routes have been used for the synthesis ofMDMA. 
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6.3. EXPERIMENTAL 
6.3.1. Synthesis of 3,4-methylenedioxyphenyl-2-propanone (PMK) 
Different ways to synthesis this ketone from safrole [176], isosafrole [53, 177, 178] 
and piperonal [179] have been reported. Figure 6.3 illustrates different methods 
used to manufacture PMK. 
O~~c:tIa 111e 
<0 ... I ---.:...,-... --.-~. 
..... fft1H,CJ4i1'tf 
fft1H, ... 
11 HCCIQH,1fP. 
21 tylO. 
Figure 6.3. Different routes to the synthesis of 3,4-methlyenedioxy-2-propanone 
(MDP-2-P) 
In this study the precursor ketone needed for synthesis of MDMA via the reductive 
amination routes and Leuckart reaction was synthesised as follows: 
To a well stirred, cooled mixture of 34g of 30% hydrogen peroxide in 150g 80% 
formic acid there was added, dropwise, a solution of 32.4g isosafrole in 120ml 
acetone at a rate that kept the reaction mixture from exceeding 400 C. This required 
a bit over 1 hour, and external cooling was used as necessary. Stirring was 
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continued for 16 hours, and care was taken that the slow exothennic reaction did 
not cause excess heating. An external bath with running water worked well. During 
this time the solution progressed from an orange colour to a deep red. All volatile 
components were removed under vacuum which yielded some 60g of a very deep 
residue. This was dissolved in 60ml of methanol, treated with 360ml of 15% 
sulphuric acid, and heated for 3 hours on a steam bath. After cooling the mixture 
was extracted with 3x75ml diethyl ether or benzene. It is recommended that the 
pooled extracts are washed first with water and then with dilute sodium hydroxide. 
Then the solvent is removed under vacuum to afford 20.6g of 3,4-methylenedioxy-
phenylacetone. The final residue may be distilled at 2.0mmll 08-112° C or at about 
1600 C at the water pump. 
6.3.2. Synthesis of MDMA 
6.3.2.1. Reductive amination routes 
Reductive amination routes have been perhaps the most frequently used method 
[56] in the manufacture of MDMA from PMK. They consist of a single-step 
technique, which requires little knowledge of chemistry, as the case with the sodium 
cyanoborohydride route, and can be described as low-pressure reductive amination 
method. As mentioned above there are four different procedures to synthesise 
MDMA via the reductive amination route. They are the sodium cyanoborohydride, 
aluminum amalgam, sodium borohydride, and Raney nickel catalysis. 
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6.3.2.1.1. Scheme 1: Aluminium amalgamation [50, 179, 180] 
o 
o 
Procedure: 
H20 (140 ml) containing 0.1 g mercuric chloride was added to 4 g of thin 
aluminium foil cut in cm squares (in a wide mouth Erlymeyer flask). Amalgamation 
was allowed to proceed until there was the evolution of fine bubbles, the formation 
of a light grey precipitate, and the appearance of occasional silvery spots on the 
surface of the aluminium. Then H20 was removed by decantation, and the 
aluminium was washed with 2x 140 ml of fresh H20. Then the residual H20 from 
final washing was removed as thoroughly as possible by shaking followed by 
addition, in succession and with swirling, of 4 ml aqueous methylamine, 10 ml 
Isopropylalcohol, Ig NaCI dissolved in 10 ml H20 and 4 ml 15% NaOH, 1 g PMK, 
and finally 20 ml isopropylalcohol. Figure 6.4 shows the reaction scheme for the 
aluminium amalgamation route for the manufacturing of MDMA from PMK. 
! I: 
o 
+ 
AI / Hg CI2 
Methylamine .-
Ethanol (80oC) 
Figure 6.4. Aluminium amalgamation route. 
MDMA 
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6.3.2.1.2. Scheme 2: Cyanoborohidride [181, 182] 
/0 
/ 
\ 
o 
Procedure 
A solution consisting of 6 mMol PMK, 60 mMol aqueous methylamine and sodium 
cyanoborohydride (15 mMol) in methanol (15 ml) was stirred at room temperature 
for 24 h. The reaction mixutre was then evaborated to dryness under reduced 
pressure and the residue suspended in dichloromethane (50ml). The 
dichloromethane suspension was then extracted with 3 N HCI (2x 50 ml) and the 
combined acid extracts made basic (PH 12) with sodium hydroxide. The basic 
aqueous suspension was then extracted with dichloromethane (2x 40 ml) and the 
combined organic extracts dried over anhydrous sodium sulphate. Filtration 
followed by evaporating the filtrate solvent which gave the product in its base form. 
The base was then treated with ethereal HCI to give the amine hydrochloride form 
which was then isolated by filtration and recrystallised from mixutres of anhydrous 
ether and absolute ethanol. Figure 6.5 shows the reaction scheme for the sodium 
cyanoborohydride route for the manufacturing ofMDMA from PMK. 
II J II + Methylamine 
Na BH3 CN 
---.- MDMA 
o HCI 
Figure 6.5. Cyanoborohydride route 
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6.3.2.2. The Leuckart reaction [52, 53, 183, 184] 
Two different routes involving the Leuckart reaction were used (Figure 6.6). Route (1) 
starts with fonnic acid and N-methylfonnamide in addition to PMK and yielded the 
intennediate N-fonnyIMDMA. Route (2) starts with fonnamide and PMK and yielded the 
intennediate N-fonnyIMDA. 
# 
°L 1 isosa~le 
glycol 
m~ ROUTE I !7Y~ ROUTE II ...., N" ~ ° • ~ "" o Ci) CHO 0L 
'--0 PM!< 0 
N-wnnyMDMA ~ ~ 
(j( 
0-:'( H ..... N'CHO 
Lo 
N-formyIMDA 
!0 I ~ N o H .... c~ 
'--0 MDMA 
Figure 6.6. Route 1 and 2 for synthesis of MDMA via the Leukart reaction 
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Route I: 
A mixture of fonnic acid (7 ml), N-methylfonnamide (0.8g), and PMK (lg) were 
refluxed at 150-170°C for 7 h with additional fonnic acid (O.4g) added periodically. 
N-fonnyIMDMA was obtained after cooling. Then concentrated HCI (30 ml) was 
added to this intennediate and refluxed for another 3 h. The reaction mixture was 
then made basicwith sodium hydroxide and the crude MDMA extracted into diethyl 
ether. The organic solvent volume was decreased and the remaining residue was 
treated with hydrogen chloride gas to yield a gelatinous brown precipitate of impure 
MDMA hydrochloride. The crude salt, dissolved in boiling methanol, was added to 
chilled acetone to fonn a crystalline product. 
Route 2: 
Fonnamide (7 ml) and PMK (1 g) were refluxed for 5 h. The solution was then 
made basic and extracted with diethyl ether. The ethereal solution was first washed 
with dilute sulphuric acid, rinsed with water and finally dried over anhydous 
sodium sulphate. The diethyl ether volume was reduced to yield a solution of N-
fonnyl-MDA. This product was then added drop-wise to lithium aluminium hydride 
and refluxed for 3 h. Excess lithium aluminium hydride was decomposed by the 
addition of ethyl acetate and then water and the resulting mixture was filtered and 
the precipitate washed with diethyl ether. The washings and the filtrate were 
combined and extracted with dilute sulphuric acid. The aqueous solution was then 
made alkaline with dilute sodium hydroxide and extracted with diethyl ether. The 
solvent was then evaporated leaving oil of crude MDMA. 
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6.3.2.3. The bromopropane route [55, 67, 182] 
This is a two step procedure including first reacting safrole with hydrobromic acid 
to give 3,4-methylenedioxyphenyl-2-bromopropane, and then taking this material 
and reacting it with methylamine to yield MDMA (Figure 6.7). This procedure has 
the advantages of not being at all sensitive to batch size, nor is it likely to "run 
away" and produce a tarry mess. It has the advantage of using cheap, simple, and 
easily available chemicals. The sole disadvantage of this method is the need to do 
the final reaction with methylamine inside a sealed pipe. This is because the 
reaction must be done in the temperature range of 120-140 C, and the only way to 
reach this temperature is to seal the reactants up inside of a bomb. This is not 
particularly dangerous, and is quite safe if some simple precautions are taken. The 
first stage of the conversion, the reaction with hydrobromic acid, is quite simple, 
and usually produces high yield of the brominated product. Figure 6.7 illustrates the 
reaction process for the bromopropane route. 
0 CH 2 Hlr 0 CH 3 
< • < 0 0 
+ 
0 C H 3 CMsNH:t 
< 
III 
0 
Figure 6.7. The bromopropane route 
Characterisation and Profiling of Ecstasy Tablets Page 120 
Procedure: 
Sample of safrole (5 g) was added to 25 ml of 48% hydrobromic acid and were 
stirred at room temperature for 7 days. The reactions were then quenched with the 
addition of crushed ice (25 ml) and extracted with ether (2x40 ml). The ether 
extracts were evaporated to dryness under reduced pressure producing oil of 
bromoisosafrole. 
This product was dissolved in ISO ml of methanol containing 40% aqueous 
methylamine (40 ml) and stirred at room temperature for 4 days. The reaction 
mixture was then evaporated to dryness and the resultant oil dissolved in 10 % Hel 
(50 ml). The aqueous acidic solution was washed with two portions of (40 ml) ether 
and then made basic (PH 12) by the addition of NaOH. The aqueous base solution 
was extracted with two portions of (50 ml) ether and the combined ether extracts 
evaporated to dryness under reduced pressure resulting in MDMA oil. 
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6.3.2.4. The nitropropene route 
A substantial amount of literature has been devoted to the synthesis and reduction 
of nitro alkanes [185-189] (Figure 6.8). 
o 
0..1 
o 
0-' 
Niuopropene route 
Figure 6.8. Diagram of the nitropropene route 
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Procedure: 
Nitroethane (7 ml) followed by 7 g cyclohexylamine were added to a solution of 7 g 
piperonal in 40 ml glacial acetic acid. The mixture was held at steam-bath 
temperature for 6 h, and cooled overnight at 10°C. Bright yellow crystals were 
formed. They were removed by filtration, recrystallised from acetic acid and then 
oven dried to yield 5 g of 1-(3,4-methylenedioxyphenyl)-2-nitropropene. This 
product (3 g) was then added, dropwise, in tetrahydrofuran, solution (2 g lithium 
aluminium hydride in 40 ml anhydrous tetrahydrofuran) and the reaction mixture 
was maintained at reflux for 36 h. After being brought back to room temperature, 
the excess hydride was destroyed with 15 ml IP A, followed by 15 ml of 15 % 
NaOH. Additional water was added to complete the conversion of the aluminium 
salts to a loose, white solid. This was removed by filtration, and washed with 
additional tetrahydrofuran. The combined filtrate and washes were stripped of 
solvent under vacuum, and the residue dissolved in dilute sulphuric acid. Washing 
with 3x 75 ml dichloromethane removed much of the colour, and the aqueous phase 
was made basic and re-extracted with 3x75 ml dichloromethane. Removal of the 
solvent yielded 2.1 g of amber oil. It was then dissolved in 60 ml of IP A, 
neutralised with concentrated HCI, and diluted with 120 ml of anhydrous EhO. 
Crystal which formed spontaneously were removed by filtration, washed with Et20 
and oven dried to yield MDA. 
6.3.3. Extraction of intermediates and reaction by-products 
Solid Phase Extraction was the method of choice for extracting intermediates and 
reaction by-products from the finished products. This procedure was used to extract 
and concentrate intermediates and reaction by-products for their analysis by gas 
chromatography-mass spectrometry [148]. 
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About 50 mg of synthesised MDMA were added to 1 ml phosphate buffer at pH 9. 
The suspension was then mixed on a rolling extractor for 30 min., centrifuged for 5 
min. and the supernatant was taken off. A period of 30 min. was required for 
complete equilibrium to be achieved. SPE procedures were carried out using Varian 
Bond Elut C 18 (200 mg) columns. The SPE column was conditioned with 10 ml of 
deionised water (to remove water-soluble impurities due to manufacture of the 
cartridge), 10 ml methanol (to solvate the column and remove other impurities), and 
10 ml deionised water (to remove excess solvation solvent). The sample was then 
applied to the column at 1-2 mVmin. The column was then washed with 10 ml 
deionised water (to remove sugars and other unwanted water-soluble compounds) 
and dried under maximum vacuum (15 psi) for 5 min. The cartridge was 
subsequently eluted with 0.7 ml isopropanol (to remove any remaining water and 
recover neutral analytes retained only by lipophilic interaction with the sorbent 
surface) followed by 1 ml ethyl acetate with 2 % ammonia (to elute basic analytes 
retained by ion-exchange interactions). These two fractions were combined and 
evaporated in a nitrogen stream to about 100 Ill. Care was taken not to evaporate to 
dryness to avoid evaporating the amphetamine impurities present in MDMA 
samples. 
6.3.4. Instrumental analysis 
6.3.4.1. Gas chromatography-mass spectrometry 
Gas chromatography was carried out usmg a Hewlett-Packard 5890 Series II 
instrument fitted with a mass spectrometry detector and equipped with a fused silica 
capillary column (HP5, 30 m x 0.32 mm i.d., 0.25 11m film thickness). Samples 
(volume 1 Ill) were injected with an injection port temperature of 2700 C at a linear 
velocity of 30 em/sec. The column oven temperature was programmed from an 
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initial temperature of 800 C (1 min) at 350 C/min to 1800 C (held for 18 min) then at 
500 C/min to 3000 C (held for 2 min). The mass spectrometer was a VG Analytical 
70/250 S double focusing mass spectrometer operated at a resolution of 1000 and 
data was recorded by a Maspec 1 data system. The MS was used in the EI mode 
with electron energy of 70 eV, and was tuned daily using PFK according to the 
manufacturer's recommendations. Mass spectra were obtained by scanning from 40 
to 600 amu at 0.3 s/scan. 
6.4. RESULTS AND DISCUSSION 
All syntheses were performed in such a manner that would be as close as possible to 
the clandestine way of manufacturing MDMA. The process of the synthesis was 
controlled at each stage to allow for retrieving a sample representing that particular 
step. Each sample was then analysed separately on GC-MS and spectra were 
collected for most intermediates, side reaction products and other impurities 
originating from precursors and other chemicals used in the synthesis. Final 
products were analysed on GC-MS after solid phase extraction to extract most of 
the MDMA out and concentrate impurities to allow for better detection and 
identification. 
6.4.1. Reductive amination route 
6.4.1.1. Amalgamation scheme 
Figures 6.9a and 6.9b show chromatograms of the final products (MDMA and by-
products) before and after solid phase extraction of the powder product respectively. 
The unextracted sample was dissolved in methanol prior to analysis on GC-MS. 
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Figure 6.9a Total ion chromatogram of unextracted MDMA prepared via 
amalgamation. 
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Figure 6.9b Total ion chromatogram of MDMA prepared via amalgamation after 
SPE. 
Since this route yields the final product (MDMA) in a single step when PMK was used as 
the precursor, no intennediates were retrieved from this process. However, the final 
product had many impurities present as seen in Table 6.1. 
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No. Name Retention Indices 
1 Piperonal 1293 
2 Safrole 1350 
3 PMK 1517 
4 MDMA 1548 
5 DMMDA 1593 
6 N-Ethyl,N-methyl-[1 ,2-(methylenedioxy)- 1980 4-(2-aminopropy 1) ] benzene 
. . Table 6.1. ImpuntIes found III MDMA synthesIs Via amalgamatlOn process . 
6.4.1.2. Cyanoborolrydride scheme 
This route also produced the final product (MDMA) in a single step after using 
PMK as the precursor. Again no intermediates were retrieved from tins process. 
However, the final product had many impurities present as seen in Table 6.2. 
No. Name 
Retention 
Indices 
1 Piperonal 1293 
2 Safrole 1350 
3 PMK 1517 
4 MDMA 1548 
5 
N,N-Dimethyl-3 ,4-methylenedioxy- 1593 
amphetamine, DMMDA 
Table 6.2. Impurities found in MDMA synthesis via cyanoborohydride route. 
Figures lOa illustrates a chromatogram of MDMA synthesised via the 
cyanoborohydride route. The sample was not subjected to any extraction procedure 
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prior to analysis on GC-MS. In Figure 6.10 b a chromatogram is shown for the 
same sample after it was subjected to a solid phase extraction procedure to 
concentrate the impurities present in the sample. 
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Figure 6.1 Oa. Total ion chromatogram of unextracted MDMA prepared via 
cynanoborohydride route. 
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Figure 6.lOb. Total ion chromatogram of MDMA prepared via cyanoborohydride 
route after it was subjected to SPE. 
6.4.2. Leuckart reaction 
This route of synthesising MDMA was more problematic and difficult to perform 
than the reductive amination routes, the amalgamation and the cyanoborohydride. 
The synthesis was performed in the first trial using 1 mg of the precursor, 3,4-
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methylenedioxy phenyl-2-propanone (PMK) which was not successful in yielding 
MDMA as the final product. Then a larger amount (5mg) of the ketone was used 
which allowed for the synthesis to proceed to the final product, MDMA. 
6.4.2.1. Route 1 
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This route did not yield MDMA even after using 5mg of the ketone as the starting 
precursor. However the first phase of the process was successful and produced the 
intermediate N-formyl MDMA - a route specific by-product- which can be used as 
a reference when identifying synthetic routes of seized street MDMA or ecstasy. 
Figure 6.11 presents a total ion chromatogram of the intermediate and Table 6.3 
provides retention indices and for the intermediate and other impurities present. 
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Figure 6.11. TIC of the intermediate N-formyl MDMA as generated via route 1 
No. Name Retention Indices 
1 Piperonal 1293 
2 safrole 1350 
3 PMK 1517 
4 N-formyl MDMA 1983 
Table 6.3 . Impurities detected in the first reflux of Leuckart reaction-route 1. 
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6.4.2.2. Route 2 
The synthesis of MDMA via the Leauckart reaction, route 2, was more successful 
than route 1. MDMA was produced in the final stage with other by-products present 
also. Figure 6.12 illustrates a total ion chromatogram of stage one of route 2. In this 
chromatogram the main product was the intermediate N-formyl MDA which is a 
synthetic route specific impurity in street ecstasy samples manufactured via route 2 
of the Leuckart reaction, in addition to a few other impurities. 
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Figure 6.12. TIC of the intermediate N-formyl MDA synthesised with Leuckart 
reaction. 
In Figure 6.13 the total ion chromatogram is shown for MDMA and other minor 
impurities in the fmal product of route 2. 
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Figure 6.13. TIC of MDMA and other impurities in a product from route 2 
reaction. 
A list of the impurities present in the final product of Leuckart reaction-route 2 is 
depicted in table 6.4 including the retention indeces and compounds names. 
No. Name 
Retention 
Indices 
1 Safrole 1395 
2 PMK 1517 
3 MDMA 1548 
4 Pyrimidine 1870 
5 N-formyl MDA 1920 
Table 6.4. Impurities in the fmal product of the Leuckart reaction-route 2 
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6.4.3. Bromopropane route 
Because of the control of the ketone (PMK) which is used with the reductive 
amination to produce MDMA, the bromination route has been an alternative 
method for clandestine laboratories. This process utilises safrole which can either be 
purchased commercially or in case where it is controlled, can be extracted from 
sassafras plant. The bromopropane route is a straitforward simple reaction which 
circumvent the need for controlled precursor chemicals. In our synthesis using this 
method, MDMA oil was obtained plus some other impurities illustrated in figures 
6.14 and 6.15 and listed with other detailed information such as retention indices in 
table 6.5. 
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Figure 6.14. TIC of the first reflux of the bromination route. 
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Figure 6.15. TIC ofMDMA synthesised with the bromination route 
No. Name Retention Indices 
1 Safrole 1395 
2 MDMA 1548 
3 3,4-methylenedioxphenylbromopropene, MDPBP 1655 
Table 6.5 . Impurities found in MDMA synthesised with bromination route. 
6.4.4. Nitropropene route 
This route yields only MDA which, can be converted with further reactions to 
produce MDMA. Because of this fact this route is not favourable to clandestine 
laboratories from economic and practicality points of view. However, for our 
purpose we performed the synthesis up to the MDA stage, which enabled us to 
obtain data on impurities normally present in such preparations. The synthesis was 
done in two steps; the first was to maintain the intermediate nitropropene which is a 
route specific impurity in street ecstasy manufactured with the nitropropene route. 
The second step was to produce the fmal product, MDA. Figure 6.16 shows a 
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chromatogram of the first step product (intermediate) while Figures 6.17a and 6.17b 
illustrate total ion chromatograms of the final product (MDA) before extraction and 
after extraction with SPE respectively. Data on the impurities found in the final 
product are summarised in Table 6.6. 
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Figure 6.16. Chromatogram of the first step product which includes the intermediate 
1-(3,4-methylenedioxyphenyl)-2-nitro-l-propene. 
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Figure 6.17a. TIC of the final product (MDA) before extraction. 
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Figure 6.17a. TIC of the final product (MDA) after extraction 
No. Name Retention Indices 
1 Piperonal 1293 
2 MDA 5.13 
3 1-[3,4-Methylenedioxyphenyl]-2-nitro-l-propene 1875 
4 N-p-3,4-methylenedioxyphenylisopropyl-3 ,4 2539 
methylenedioxybenzaldimine 
Table 6.7. Impurities found in MDA synthesised with the nitropropene route. 
6.5. CONCLUSION 
Synthesis of MDMA and MDA using different synthetic routes such as the 
reductive amination (the amalgamation and the cyanoborohydride schemes), the 
Leuckart reaction using two routes, the bromination route, and the nitropropene 
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route was perfonned. It was possible to obtain authentic samples of compounds 
found in illicit preparations including impurities. 
The synthesis of MDMA and MDA via the most widely utilised methods by the 
clandestine laboratories have provided reference data in the form of mass spectra 
and retention indices for the major compounds and impurities nonnally present in 
illicit preparations. The data can be used for the detection and identification of 
impurities in illicit samples and allow for drawing conclusions on the synthetic 
routes for these samples and perhaps identify new impurities not encountered 
before. 
Theoretical data in the fonn of mass spectrum or retention indices are useful. 
However, each analytical instrument has it is own identity and therefore the results 
obtained can vary considerably in certain cases. From this fact it is recommended 
that an in-house synthesis of illicit drugs is vital and provides original samples and 
data using the same analytical conditions such as extraction methods, chemicals and 
solvents, and instrumentation. 
There are some impurities that can be considered as route specific and their 
identification provides infonnation as to the method of synthesis used by the 
clandestine laboratories for the preparation of illicit drugs. Mass spectra of some 
intennediates and other route specific impurities are seen in Figures 6.18a to 6.18f. 
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Figure 6.18a. Mass spectrum of DMMDA, a reductive amination route specific 
impurity. 
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Figure 6.18b. Mass spectrum of the Leuckart intermediate N-formyl MDMA. 
100 16 3 
90 135.2 
80 .... 
70 
60 
50 73 ...... 
40 
30 40.4 
78.9 
207.3 
20 
10 
0 
40 60 80 100 
Low Resolution M/z 
Figure 6.18c. Mass spectrum of the Leuckar intermediate N-formyl MDA. 
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Figure 6.18d. Mass spectrum of 3,4-methylenedioxyphenyl-2-hromopropane 
(MDPBP), an intermediate of the bromination routre. 
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Figure 6.18e. Mass spectrum of 1-(3,4-methylenedioxypheyl)-2-nitro-l-propene, an 
intermediate of the nitropropene route. 
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Figure 6.18f. Mass spectrum of N-I3-3,4-methylenedioxyphenylisopropyl -3,4 
methylenedioxybenzaldiirnne 
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7. IMPURITIES IN SEIZED ECSTASY TABLETS 
7.1. INTRODUCTION 
Determination and quantification of impurities or minor components present in 
seized drugs provide vital information. These impurities originate from precursors, 
natural raw materials, solvents used in the synthesis, side-reaction and 
intermediates. They should be distinguished from diluents and adulterants which 
have been added deliberately. Certain impurities identified in illicit drugs are route 
specific impurities (e.g. intermediates). 
The type of information provided through the identification of impurities include, 
determination of the synthesis route [51], identification of precursor chemicals used 
[56], and determination of compounds which may represent public health risks [5]. 
Clandestine production of 3,4-methylenedioxymethamphetamine, MDMA was 
discussed in detail [51, 56] and many different synthetic routes such as the reductive 
amination route, the Leuckart method, the bromopropane route, the Ritter reaction, 
the nitropropene and the cinnamic acid routes were reviewed. Safrole, isosafrole, 
piperonal, and 3,4-methlyenedioxy phenyl-2-propanone are the main precursors 
used. MDMA is almost always illicitly manufactured and because of the lack of 
quality control in clandestine laboratories, impurities arising from precursor 
chemicals, intermediates, and other impurities are also produced and will be present 
in the final product. In a review [51] mass spectral data of impurities in MDMA 
samples synthesised by the reductive amination route, the Leuckart reaction, the 
nitropropene route, and the bromopropane route were reported. Impurities in illicit 
MDMA samples were also isolated by TLC and detected by mass spectrometry and 
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IH-NMR [54]. Renton et al [52] provided data for precursor intermediates, and 
reaction by-products in illicit MDMA. They used these results for establishing the 
route of synthesis in actual casework. Verweij reported [51] structure elucidation 
for impurities in illicit MDMA prepared by the low-pressure reductive amination of 
3,4-methiyenedioxy phenyl propanone with methylamine. The presence of the 
intermediate imine (l,2-methylenedioxy-4-2-N-methyimino propyl benzene) 
provided information about the synthetic route. 
In this chapter confiscated ecstasy tablets containing MDMA as the principal 
component were extracted using an optimised, solid phase extraction procedure. In 
this procedure extraction and concentration of impurities in ecstasy tablets were 
done to allow for their detection and identification by gas chromatography-mass 
spectrometry . 
7.2. EXPERIMENTAL 
7.2.1. Chemicals and reagents 
Samples of ecstasy tablets (12 samples) used in the study were provided by the 
Forensic Science Services, Metropolitan Laboratory, London. All reagents used 
were of analytical or HPLC grade. Solid phase extraction columns (Bond Elut®) 
were obtained from Varian Associates, Harbor City, CA, USA. 
7.2.2. Extraction procedure 
Solid Phase Extraction was the method of choice for extracting intermediates and 
reaction by-products from the finished products. This procedure was used to extract 
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and concentrate intennediates and reaction by-products for their analysis by gas 
chromatography-mass spectrometry. 
About 50 mg of ground and homogenised ecstasy powder were added to 1 ml 
phosphate buffer of pH 9. The suspension was then mixed on a rolling extractor for 
30 min., centrifuged for 5 min. and the supernatant was taken off. A period of 30 
min. was required for complete equilibrium to be achieved. SPE procedures were 
carried out using Varian Bond Elut C 18 (200 mg) columns. The SPE column was 
conditioned with 10 ml of deionised water (to remove water-soluble impurities due 
to manufacture of the cartridge), 10 ml methanol (to solvate the column and remove 
other impurities), and 10 ml deionised water (to remove excess solvation solvent). 
The sample was then applied to the column at 1-2 mllmin. The column was then 
washed with 10 ml deionised water (to remove sugars and other unwanted water-
soluble compounds) and dried under maximum vacuum (15 psi) for 5 min. The 
cartridge was subsequently eluted with 0.7 ml isopropanol (to remove any 
remaining water and recover neutral analytes retained only by lipophilic interaction 
with the sorbent surface) followed by 1 ml ethyl acetate with 2 % ammonia (to elute 
basic analytes retained by ion-exchange interactions). These two fractions were 
combined and evaporated in a nitrogen stream to about 100 Ill. Care was taken not 
to evaporate to dryness to avoid evaporating the amphetamine impurities present in 
ecstasy samples. 
7.2.3. Instrumental 
7.2.3.1. Gas chromatography-mass spectrometry 
Gas chromatography was carried out using a Hewlett-Packard 5890 Series II 
instrument fitted with a mass spectrometry detector and equipped with a fused silica 
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capillary column (HP5, 30 m x 0.32 mm i.d., 0.25 ~m film thickness). Samples 
(volume 1 ~l) were injected with an injection port temperature of 2700 C at a linear 
velocity of 30 cm/sec. The column oven temperature was programmed from an 
initial temperature of 800 C (l min) at 350 C/min to 1800 C (held for 18 min) then at 
500 C/min to 3000 C (held for 2 min). The mass spectrometer was a VO Analytical 
70/250 S double focusing mass spectrometer operated at a resolution of 1000 and 
data was recorded by a Maspec 1 data system. The MS was used in the EI mode 
with electron energy of 70 eV, and was tuned daily using PFK according to the 
manufacturer's recommendations. Mass spectra were obtained by scanning from 40 
to 600 amu at 0.3 s/scan. 
7.3. RESULTS AND DISCUSSION 
In this chapter the objectives were to perform comparative analysis on street ecstasy 
tablets seized between 1995 and 1996. Two different approaches were performed to 
establish a comparative study on the illicit ecstasy samples. The first approach was 
to identify the major impurities present in the impurity profiles obtained for the 
samples after subjecting them to solid phase extraction and instrumental analysis 
using gas chromatography mass spectrometry. Identification of the main impurities 
allowed for elaborating on the synthetic routes of these samples. The second 
approach was to use a comparison procedure based on visual comparison of 
impurity profiles to cluster the samples into smaller groups and relate those with 
similar impurity profiles to common batches. 
Pure standards of MDMA, MDEA, safrole, piperonal, and 3,4-methylenedioxy 
phenyl-2-propanone (PMK) were analysed on OC-MS and their data including 
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retention indices and mass spectra were used for identification of impurities in street 
samples. Figures 7.1 a to 7.1 e illustrate the mass spectra for these standards. 
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Figure 7.la. Mass spectrum ofMDMA. 
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Figure 7.1b. Mass spectrum ofMDEA. 
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Figure 7.1 c. Mass spectrum of safrole. 
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Figure 7.1 d. Mass spectrum of piperonal. 
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Figure 7.1e. Mass spectrum ofPMK. 
Impurity profiles are often observed in illicitly prepared drug samples, as they are 
not usually purified to any great degree after manufacture. In the case of illicitly 
prepared amphetamine, the presence of "route specific" impurities is used to 
established the manufacturing processes [47]. Applying this analogy to MDMA, the 
identification of the intermediate N-formyl MDMA revealed that the Leuckart 
reaction (route 1) was used in the manufacture of samples 1, 2, 7, 8, 9, 10, 11, and 
12. Samples 3, 4,5, and 6 synthesis route's were unidentified. The major impurities 
present in samples 1, 2, 7, 8, 9, 10, 11, and 12 were identified and their data are 
summarised in Tables 7.1. 
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Compound Compound l 'oillpound ( 'ol11polllld ,I I 2 3 
Retention 3.49 5,04 5,28 8.28 time 
Retention 1293 1517 1548 1983 Index 
Na me Piperonal PMK MDMA N-formyl MDMA 
Syn th e..~ is route: The Leuckart reaction 
Table 7.1. Data of compounds in sample 1 
Impurity profiles of the analysed street ecstasy samples (Figures 7.2a to 7.2L) were used 
for the visual comparison of the analysed samples. 
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Figure 7.2a. Impurity profile of sample 1 
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Figure 7.2b. Impurity profile of sample 2 
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Figure 7.2c. Impurity profile of sample 3 
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Figure 7.2d. Impurity profile of sample 4 
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Figure 7.2e. Impurity profile of sample 5 
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Figure 7.2f. Impurity profile of sample 6 
Characterisation and Profiling of Ecstasy Tablets 
100 
90 
80 
70 
60 
50 
40 
30 
20 
10 
3:27 
5:30 
6:10 
7:52 8:34 ....... 12:13 13:35 
.... , ... 
o I" i 
o 
iii iii Iii iii iii iii iii iii iii iii iii iii Iii iii iii iii iii iii iii iii 
200 400 600 800 1000 1200 
Scan Number 
Figure 7.2g. Impurity profile of sample 7 
6:51 
5:30 
.............. 
8:29 10:09 12:12 13:34 
Figure 7.2h. Impurity profile of sample 8 
100 5:31 5:41 
90 ....... .......... 
80 
70 
60 
50 
40 
30 
20 
10 
0 
0 200 400 600 800 1000 1200 
Scan Number 
Figure 7.2i. Impurity profile of sample 9 
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The analysed samples were compared visually. Out of the 12 samples analysed, 7 
samples were clustered into 3 different groups while the other 5 samples showed no 
similarity with other samples. Figures 7.3, 7.4, and 7.5 illustrate overlays of similar 
impurity profiles. This form of comparison of impurity profiles helps group samples 
together and with the aid of other analytical procedures such as physical analysis 
and other organic methods can provide useful information for drugs intelligence. 
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7.4. CONCLUSION 
In this chapter 12 different ecstasy samples seized during the years 1995 and 1996 
within the UK were subjected to comparative analysis through the use of solid 
phase extraction and gas chromatography-mass spectrometry. The chemical 
analysis included detection and identification of key impurities (route specific) 
which allowed for determination of the synthesis route for seven samples. 
Comparison of the impurity profiles of the analysed samples was also performed for 
the purpose of relating these samples to common source or batch. Visual 
comparison of the impurity profiles gave an indication of possible similarity of 
samples 1 & 2, 3 & 5, and 9, 10, & 11. Further analysis of the samples using other 
analytical tools may reveal more information that can help in drawing conclusions 
regarding the source of these samples. 
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8. CONCLUSIONS AND FUTURE WORK 
8.1 WHAT HAS BEEN ACHIEVED? 
This project has been on the subject of drug profiling with focus on the ring-
substituted amphetamine; MDMA or ecstasy as it is widely called. Among the main 
objectives of this study was the development and optimisation of a new extraction 
procedure such as solid phase extraction, for impurities in seized ecstasy tablets. 
The instrumental analysis of impurities found in ecstasy tablets usually requires a 
preliminary extraction process to extract, isolate, and concentrate these impurities 
from the total tablet content. In the process, interfering materials are removed, and 
the required substances are concentrated into a solvent that is suitable for 
introduction into the instrument. Although lengthy and time-consuming, these 
procedures are of paramount importance to remove the principal component(s), 
diluents and adulterants, and concentrate impurities. 
An evaluation of a comparison procedure of LLE and SPE for extracting impurities 
in ecstasy tablets for profiling purposes was done. Solid phase extraction of 
impurities in ecstasy tablets proved to be more efficient than the traditional liquid-
liquid extraction. SPE provided impurity peaks with higher intensities than did LLE 
and a shorter extraction time. 
Other area of research was the use of infrared technology for profiling ecstasy 
tablets since only chromatographic methods have been studied. Infrared 
spectroscopy and in particular fourier transform infrared, FTIR, can serve as 
another tool for comparing drug seizures. Each exhibit has its own characteristic 
spectrum, and comparison between the different spectra gives a gross estimate of 
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the similarity or dissimilarity between the different exhibits. FTIR has some 
discriminating capability to classify powders into a large number of groups, and 
consequently can be used for gross comparison or as screening tool. Drug 
intelligence involves two main streams with regard to comparative analysis or drug 
profiling. The first includes court cases such as sample/sample comparison and 
relating user to a dealer to prove conspiracy. The second task for drug intelligence 
involves establishing relationships between seizures and providing information on 
the networking of samples, which may be of use in investigating major trafficking 
operations. In such operation the laboratory may have to analyse many samples. 
FTIR analysis can be utilised for such operation as an elimination tool for its sheer 
simplicity and short analysis time. The developed method allowed for a short 
analysis at under 1 minute for each sample. 
The second stage of the experimental part of the thesis dealt with synthesis of 
MDMA to acquire authentic intermediates and other impurities usually encountered 
in illicitly produced samples. These impurities were analysed and their retention 
indices and mass spectra were recorded. Synthesis of MDMA and MDA using 
different synthetic routes such as the reductive amination (the amalgamation and the 
cyanoborohydride schemes), the Leuckart reaction using two routes, the 
bromination route, and the nitroprpene route was also performed. 
Theoretical data in the form of mass spectra or retention indices are useful. 
However, each analytical instrument has it is own identity and therefore the results 
obtained can vary considerably. The synthesis of MDMA and MDA via the most 
widely utilised methods by the clandestine laboratories have provided reference 
data in the form of mass spectra and retention indices for most of the major 
compounds and impurities which are normally present in illicit preparations. This 
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data was used for the detection and identification of impurities in case samples. 
There are some impurities that can be considered as route specific and their 
identification can provide information as to the method of synthesis used by the 
clandestine laboratories for the preparation of illicit drugs. Once data on the 
authentic sample were established, ecstasy tablets confiscated within the UK 
containing MDMA were analysed and identification of marker impurities was 
performed which allowed for the determination of the synthetic routes for some of 
these exhibits. 
8.1.1. Does it work? 
It is generally accepted that drug profiling is a complex science [70] and that it 
requires a great deal of expertise and knowledge on the subject. However, it can be 
a successful procedure if all the required parameters are met. The basis of 
comparative analysis for strategic and tactical intelligence purposes is the 
comprehensive examination of the chemical and physical characteristics of a drug 
exhibit towards the establishment of the degree of commonality of origin with 
another specific sample or group of samples. Therefore, it deals with the 
development of analytical procedures allowing the collection of valuable data on 
every drug seizure so as to obtain an exhaustive description of it. For this purpose 
the profiling procedure should not rely on a single analytical technique and a 
database covering the main features (criteria for comparison) of the analysed 
exhibits should be considered. 
8.1.2. Is it useful? 
Characterisation and classification of illicit drug samples is an important objective 
for drug intelligence, It establishes relationships between seizures and may provide 
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evidence of links between dealers and users. Not only does this allow the matching 
of samples in local cases of dealing but also provides intelligence information on 
the origin and distribution of samples which may be of use in investigating major 
trafficking operations. Drug profiling methods also provide estimation of the 
clandestine manufacturing and illicit drug trafficking and distribution trends in 
addition to information on precursor chemicals used in illicit drug synthesis which 
will allow for their control. Drug profiling has proved that it is a useful science in 
real court cases [17] and in routine laboratory work [72, 74], as a tool for drug 
intelligence and for monitoring clandestine manufacturing of illicit drugs [5, 8, 56]. 
8.2. WHAT REMAINS TO BE DONE (FUTURE WORK)? 
Comparative analysis and drug profiling procedures as mentioned in chapter 3 
involve the use of different methodologies and analytical analyses. Those concerned 
with impurity profiling include identification of key impurities or comparison of 
impurity profiles, usually involve set of procedures such as extraction of impurities 
by different extraction methods, instrumental analyses of the extracts followed by 
data acquisition, manipulation and interpretation. Each step can be performed by 
different approach. Extraction of impurities has been widely done using liquid-
liquid extraction. In the study solid phase extraction has been used as an alternative 
method. Further work in the future can be done on examining the use of automated 
solid phase extraction procedure. The automated SPE procedure will provide an 
attended extraction saving precious analyst time and manpower, establishing more 
consistency and repeatability in the analysis, and allowing for a total automated 
procedure including extraction, chromatography and data and statistical analysis. 
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The use of other analytical instruments such as capillary electrophoresis (CE) gas 
chromatography-fourier transform infrared spectroscopy (GC-FTIR) may be 
explored as tools for drug profiling procedures. Other areas of future work also 
include developing new computer-assisted statistical analysis for comparison of 
impurity profiles that may allow for rigorous comparative analysis and higher 
power of discrimination. 
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REFERENCE: Rashed AM. Anderson RA. King LA. Solid-phase 
extraction for profiling of ecstasy tablets. J Forensic Sci 2000;45(2): 
413-417. 
ABSTRACT: A solid-phase extraction (SPE) procedure has been 
developed for impurity profiling of illicit tablets containing 3,4-
methylenedioxy-N-methyl-amphetamine (MDMA, ecstasy). Fol-
lowing initial comparison of liquid-liquid extraction and solid-
phase extraction, SPE was found to be preferable because it 
afforded higher extraction efficiencies and shorter extraction times. 
Procedure blank samples were also analyzed to identify constituents 
of the extracts which did not originate in the ecstasy tablets. 1be de-
veloped procedure was subsequently applied to 12 samples of 
seized ecstasy tablets and a comparison was made of these samples 
to determine similarities and obtain inferences with respect to com-
monality of origin. 
KEYWORDS: forensic science, solid-phase extraction, ecstasy, 
profiling, impurities 
Profiling of clandestinely manufactured drugs is concerned with 
the detailed chemical examination of impurities derived from their 
manufacture, if the drugs are synthetic. or co-extracted. if they are de-
rived from natural products. These should be distinguished from dilu-
ents and adulterants which have been added deliberately. Many work-
ers have reported on profiling of amphetamine (1-8), 
methamphetamine (9-12). heroin (13-18). cocaine (19-25). and 3,4-
methylenedioxy-N-melhyl-amphetamine (MDMA) (2Cr31). Profil-
ing serves as a tool to relate different street drug seizures to a common 
source. to determine the origin of drugs manufactured from natural 
sources (32) or synthetic routes for synthetic drugs. and to identify im-
purities found in illicit drugs which may cause public health risks be-
cause of their inherent chemical or biological hazards (33). 
"Ecstasy" is the common name for MDMA. a synthetic hallu-
cinogenic amphetamine. which has become one of the most widely 
used illicit substances in Europe. It is almost always produced in 
clandestine laboratories and very often contains various impurities 
such as reaction by-products. synthetic intermediates and contami-
nants from reagents. which accumulate during the synthetic se-
quence because of the lack of quality control in clandestine labora-
tories. These impurities often represent a very small percentage of 
the total weight of the finished product and their analysis by in-
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strumental methods usually requires a preliminary extraction pro-
cess to isolate and concentrate the analytes from the total tablet 
content. In the process. interfering materials are removed and the 
target substances are concentrated into a solvent that is suitable for 
introduction into the analytical instrument selected. Although 
lengthy and time-consuming. these procedures are of paramount 
importance, resulting in the removal of the major constituents-the 
active drug substances. diluents and adulterants-and concentra-
tion of the minor impurities. 
Liquid-liquid extraction (LLE) of impurities from street drugs has 
until now been the method of choice for sample preparation. Many 
problems are associated with LLE. including lengthy handling time 
and the need to concentrate the sample after extraction. Sample 
preparation techniques using solid-phase extraction (SPE) have not 
been widely used for the profiling of street drugs. and there are few 
reports in the literature (34). In this study. SPE and gas chromatog-
raphy (Ge) were used for the extraction and analysis of impurities in 
ecstasy tablets obtained from different street drug seizures. and com-
parisons were made of their chemical signatures (profiles). 
Experimental 
Materials and Reagents 
Sixteen different samples of ecstasy tablets used in the study were 
provided by the Forensic Science Services. Metropolitan Laboratory, 
London. All reagents used were of analytical or high-pressure liquid 
chromatography (HPLC) grade. Solid-phase extraction columns 
(Bond Elut®) were obtained from Varian Associates, Hamor City, CA. 
Gas Chromatography 
Gas chromatography was carried out using a Hewlett-Packard 
5890 Series II instrument fitted with a flame ionization detector and 
equipped with a fused silica capillary column (HP5. 30 m X 0.32 
mm inside diameter 0.25 11m film thickness). Samples (volume I 
ILL) were injected with an injection port temperature of 270°C at a 
linear velocity of 30 cm/s. The column oven temperature was pro-
grammed from an initial temperature of 80°C (I min) at 35°C/min to 
180°C (held for 18 min) then at 50°C/min to 300°C (held for 2 min). 
Solid-Phase Extraction Versus Liquid-Liquid Extraction 
A comparison of SPE and LLE was carried out to evaluate the 
use of SPE as an alternative extraction procedure to LLE. Ten por-
tions of a ground and homogenized ecstasy sample. 50 mg each. 
were separated into two groups of five portions. One group was 
subjected to LLE. the other to SPE. Both groups were analyzed by 
gas chromatography/flame ionization detection (GC/FID) using 
the conditions mentioned above. 
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Solid-Phase Extraction 
The tablets were crushed and 50 mg of the homogeneous pow-
der were added to I mL phosphate buffer at pH 9. The suspension 
was then mixed on a rolling extractor for 30 min, centrifuged for 
5 min and the supernatant was taken off. A period of 30 min was 
required for complete equilibrium to be achieved. SPE procedures 
were carried out using Varian Bond Elut C 18 (200 mg) columns. 
The SPE column was conditioned with 10 mL of deionized water 
(to remove water-soluble impurities due to manufacture of the car-
tridge), \0 mL methanol (to solvate the column and remove other 
impurities), and \0 mL deionized water (to remove excess solva-
tion solvent). The sample was then applied to the column at I to 2 
mL/min. The column was then washed with \0 mL deionized wa-
ter (to remove sugars and other unwanted water-soluble com-
pounds) and dried under maximum vacuum (15 psi) for 5 min. The 
cartridge was subsequently eluted with 0.7 mL isopropanol (to re-
move any remaining water and recover neutral analytes retained 
(lnly by lipophilic interaction with the sorbent surface) followed by 
I rnL ethyl acetate with 2% ammonia (to elute basic analytes re-
tained by ion-exchange interactions). 1bese two fractions were 
combined and evaporated in a nitrogen stream to about 100 .... L. 
Care was taken not to evaporate to dryness to avoid evaporating 
the amphetamine impurities present in ecstasy samples. 
liquid-Liquid Extraction 
Phosphate buffer (I mL, pH 9) was added to 50 mg of the same 
homogeneous powder used for the SPE procedure. The solution 
was then mixed on a rolling extractor for 30 min. Ethyl acetate (I 
mL) was added to the solution and the tube was again mixed on a 
tolling extractor for 30 min. A period of 30 min was required for 
complete equilibrium to be achieved. The sample was then cen-
trifuged for 5 min at 3000 rpm and the organic layer was taken off 
and evaporated in a nitrogen stream to about 100 .... L, with care be-
ing taken not to evaporate to dryness. At this stage 100 .... L of the 
internal standard, triethylamine, was added. Only I .... L of the sam-
ple was injected in the GC-FID. 
Blank Extraction by SPE and ILE 
Two blank aliquots of phosphate buffer were extracted by SPE 
and LLE using the same solvent and cartridges used in the rest of 
the work to ensure that analytical artifacts were not introduced. 
Application to Real Case Samples 
Twelve different samples of seized ecstasy tablets were analyzed 
using solid-phase extraction and GC-FID. The extraction proce-
dure and the GC-FID conditions were as described above. 
Comparison of Tablets from Same Seizure 
Two tablets from the same seizure were chosen at random and 
were analyzed for the purpose of establishing common origin. Each 
tablet was ground, extracted, and analyzed separately to avoid 
cross contamination. 
Results and Discussion 
Solid Phase Extraction Versus Liquid-Liquid Extraction 
Five portions of the same ecstasy sample were extracted by SPE 
and analyzed by GC-FID. The principal peaks of chromatograms 
representing impurities of each portion were numbered. The ratios 
of their peak areas to that of the internal standard and the means of 
the relative peak areas were calculated. The same procedure was 
performed for the other five portions extracted by LLE. 
To evaluate the data collected from the various chromatograms 
of ecstasy samples extracted by SPE and LLE, statistical analysis 
was performed to compare the means of the relative peak areas of 
seven major impurity peaks present in the chromatograms. The 
two-sided t-test was used to assess if means of the selected peaks 
were significantly different for each extraction method. In addi-
tion, a comparison was made of the means of relative peak areas 
of peaks number 1, 2, and 7 for each extraction method and the p 
value was calculated using a computer software package 
(Minitab). The p value of each t-test as shown in Table I indicated 
that there are significant differences between the evaluated means. 
Since peak areas for samples extracted by SPE were larger than 
those extracted by LLE, and the p values showed significant dif-
ferences between the mean values, it is safe to conclude that SPE 
provided a better extraction yield of impurities in ecstasy samples. 
Another illustration of the differences in the mean of relative 
peak area of peaks 1, 2, and 7 is shown in Fig. 1 where SPE yielded 
better peak recovery than LLE. 
Blank Extraction by UE and SPE 
Blank extracts showed no major peaks especially at the retention 
time as the ecstasy impurities peaks where present. Figure 2 
demonstrates chromatograms of two blank samples extracted by 
LLEand SPE. 
Applications to Seized Samples 
The magnitude of inter- and intra-batch variation of impurity 
profiles governs the establishment of a "common source." Intra-
batch variation should be less than inter-batch variation since sam-
ples belonging to the same batch expected to show more similari-
ties than samples belonging to different batches. 
Comparison of Different Seizures (Inter-Sample Variation) 
Ecstasy samples from 14 different seizures (packages) were ex-
tracted by solid-phase extraction and analyzed by GC-FID for the pur-
pose of establishing commonality. Figure 3 shows a comparison of im-
purity profiles of three ecstasy samples from three different seizures. 
The above impurity profiles allowed for visual comparison of 
three different ecstasy samples. It is clear that they contain great 
variations and consequently do not belong to a common batch 
(source). 
TABLE I-Two sample t-test results of peaks 1.2. and 7 for both SPE 
and LLE extraction methods. 
Two Sample t-test for Peak I 
95% c.l. for LLE I - SPE I: (-1.859. -0.12) 
t-Test LLE I = SPE I (not=): t = -2.57 
p = 0.030 OF = 9 
Two Sample t-test for Peak 2 
95% C.I. for LLE 2 - SPE 2: (-2.564, -2.053) 
I-Test LLE2 = SPE 2 (not=): t = -20.82 
p = 0.001 OF = 9 
Two Sample I-test for Peak 7 
95% c.l. for LLE 7 - SPE 7: (-0.176. -0.057) 
I-Test LLE 7 = SPE 7 (not=): I = -4.63 
p = 0.0025 OF = 9 
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Comparison of Tablets from Same Seizure (Intra-Samp/t. 
Variation) 
Impurity profiles of two randomly chosen ecstasy tablets from 
the same seizure (package) were obtained using solid-phase ex-
traction and GC-FID. The generated impurity profiles showed sim-
ilarities indicating that both samples belong to the same hatch. Pig-
ure 4 demonstrates an overlay comparison of their impurity profiles 
showing little variation. 
Future Work 
Among the numerous advantages of using solid-phase extraction 
for profiling of illicit drugs are efficiency. no cross contamination 
of phases. and no emulsion problems. as with LLE. due to the pres-
ence of fatty acids in ecstasy tablets. Further profiling can be very 
difficult with a sample of high purity since the impurity profile is 
dependent on impurity abundance in the sample. An excellent ex-
traction of impurities in high-purity drug exhibits by LLE requires 
repeated extractions and the use of a large volume of solvents, 
which can cause loss of analytes and consequently poor impurity 
profiles. SPE can provide excellent impurity profiles with superior 
selectivity. high recovery. and reduced organic solvents consump-
tion. Finally. there is the possibility of automating the extraction 
procedure. which is more easily automated with SPE than with 
LLE. The automated SPE procedure will provide an attended ex-
traction. saving precious analyst time and manpower. establishing 
more consistency and repeatability in the analysis, and allowing for 
a total automated procedure including extraction, chromatography, 
and data and statistical analysis. 
Conclusion 
Solid-phase extraction of impuritie.~ in ecstasy tahlets proved to 
be more efficient than the traditional liquid-liquid extraction. SPE 
provided impurity peaks with higher intensities than did L1.E ami 
a shorter extraction time. Street samples of ecstasy were analyzed 
for profiling purposes using the SPE procedure. Samples from 
different seizures (packages) showed little variations and great 
similarities, indicating common batch origin. while those from 
different packages showed great variations. indicating different 
batch origin. 
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Abstract: Optimisation of a solid phase extraction procedure for the profiling of ecstasy 
tablets was done. Three main parameters of the extraction procedure were examined and 
evaluated. These parameters were pH, eluting solvents, and SPE columns. A range of pi I 
values from 5 to 10 were examined for extracting impurities in ecstasy tablet and pi I ') was 
determined to be the optimum pH. Four different eluting solvents. ethyl acetate, 
dichloromethane, hexane, and isooctane, were evaluated. Ethyl acetate produced un impurity 
profile with higher yield than the other solvents examined. Out of eight diflcrent SPE 
columns from two different manufacturers, Varian Bond Elut C 18 200mg produced the best 
impurity profile. The impurity profiles were stable over a period of t<lUr weeks. 
Keywords: Optimisation, Profiling, Impurities, Ecstasy, SPE 
I. Introduction 
Illicit ecstasy tablets produced in clandestine laboratories usually contain variolls 
impurities such as, reaction by-product, intermediates and contaminants within rca~cnts. 
accumulate as a chemical reaction proceeds because of the luck of quality control in thesc 
laboratories. Many of these impurities have been isolated and identilied 11-41. Thcsc 
impurities provide chromatographic profiles that allows for comparison of dillcrcnt exhibits 
for the fact that samples originate from the same batch almost certainly havc thc same 
number and relative amounts of identical impurities [5]. 
The instrumental analysis of impurities found in ecstasy tablets usually rcquircs a 
preliminary extraction process to extract. isolate, and concentrate these impurities from thc 
total tablet content. In the process, interfering materials are removed. and the rcquircd 
substances are concentrated into a solvent that is suitable for introduction into the instrumcnt. 
The impurities found in illicit tablets are extracted. aller crushing the tablct and dissolving thc 
fine homogeneous powder in deionised water or butTer solution which l(lrnlS un uqueous 
matrix, into an organic solvent. Although lengthy and time-consuming. these procedurcs are 
of paramount importance to remove the principle component(s). diluents and udultcrants. and 
concentrate impurities. 
Solid-phase extraction (SPE) procedures have been used with various types of 
samples, from biological fluids to environmental pollutants. and the literature is full of 
articles on work done in this regard. But only one paper has been cited on the use of SPl: I(lr 
the extraction of impurities found in clandestine drugs 161. In this project special emphasis 
will be given to the use ofSPE for the extraction of impurities in illicit (ecstasy) tablets. This 
paper describes an optimisation method of a solid phase extraction procedure t(lr profiling 
ecstasy tablets. 
2. Experimental 
2.1 Optimising SPE Procedure 
The optimisation of SPE procedure was done in three main steps 
1. Examination of the best extraction pH 
2. Evaluation of eluting solvents used for extracting impurities 
3. Assessment of different SPE columns 
2.2 Examination of the best extraction pH 
The tablets were crushed and 50 mg of the homogeneous powder were added tu I ml 
phosphate buffer at pH 9. The suspension was then mixed on a rolling extractor I()r 30 min .. 
centrifuged for 5 min. and the supernatant was taken oiT. A pcriod of 30 min. was required Illr 
complete equilibrium to be achieved. A SPE column (Bond Elut Certify 130 mg) was 
conditioned with 10 ml of deionised water (to remove water-soluble impurities due to 
manufacture of the cartridge), 10-ml methanol, and 10 ml dcionised water. The smnplc 
(supernatant) was then applied to the column at 1-2 ml/min. The column was then wast}(~d 
with 10 ml deionised water (to remove sugars and other unwanted water-soluble compounds) 
and dried under maximum vacuum (15 psi) for 5 min. The sample was subsequently washed 
with 0.7 ml isopropanol (to remove any remaining watcr and reduce lipophilic bonding 
between the analytes and the sorbent surface) followed by 1 ml ethyl acetate with 2 % 
ammonia {to elute freed analytes by eliminating ion-exchange interactions}. The collected 
sample was evaporated in a nitrogen stream to about 100 ~I. with care being taken not to 
evaporate to dryness. The pH values of the phosphate buffer ranged from 5 to 10. 
2.3 Gas Chromatography 
The GC was an Hewlett-Packard 5890series II with flame ionization detector. One ~l 
of sample was injected with an injection port temperature of 270°C, splitless mode. Gas 
chromatography was carried out using a fused silica capillary column (HP5, 30 m x 0.32 mm 
Ld., 0.25 ~m film thickness) programmed from an initial temperature of 80°C (1 min) at 
35°C/min to 180°C (held for 18 min) then at 50°C/min to 300°C (held for 2 min). 
2.4 Evaluation of eluting solvents for the one with most impurities extracted 
The same extraction procedure was repeated under the optimum pH determined above 
using four different eluting solvents, ethyl acetate, dichloromethane, hexane, and isooctane. 
The relative peak areas were calculated and bar charts were drawn for the main peaks to 
determine the best eluting solvent 
2.5 Assessment of different SPE columns 
Once the optimum extraction pH and the best eluting solvent were determined an 
assessment of different SPE columns was done using the same extraction procedure as above. 
The columns used for the assessment study were, Bond Elut CI8 200 mg, CI8 500mg, 
Certify 300mg, and Certify 130mg (Varian) and Isolute C8 200mg, C8 500mg, C 18 200mg, 
and CI8 500mg9 International Sorbent Technology). The relative peak areas were calculated 
and a bar chart was drawn for the main peaks to determine the performance of each type of 
SPE column. Throughout all the extraction procedures performed above only one type of 
ecstasy tablet was use to assure that any variations were due to different extraction procedure 
parameters not due to different samples. 
2.6 Blank Extracts 
The same extraction procedure was used with blank extracts to ensure impurities other 
than those present in the tablets were not present. 
2.7 Stability of Extracts during Storage 
Extracts were stored at 4°C in the dark, and were re-analysed over a period of 4 weeks 
to check their stability 
2.8 Application to Real Samples 
Three ecstasy samples seized from different individuals at different locations were 
analysed on the optimised conditions. 
3. Results and Discussion 
The optimisation procedure was done on a sequence to allow the use of the optimum 
determined parameter for the next step of the optimisation procedure. 
3.1 Examination of the best extraction pH 
Six different pH values (5-10) were examined using the same eluting solvent (ethyl 
acetate) and the same SPE column (Bond Elut Certify 130mg). The SPE procedures were run 
for all pH range on portions of the same homogeneous ecstasy powder using the same steps 
all the time. Figure 1 illustrates the superiority of extracting with pH 9 over other pH values. 
The optimum pH at 9 yielded better impurity profile with more impurity peaks present 
allowing for a better chemical signature comparison. 
3.1 Evaluation of eluting solvents for the one with most impurities extracted 
In the evaluation of the eluting solvents procedure four solvents were used; ethyl acetate, 
hexane, dichloromethane and isooctane using the optimised pH 9 and Bond Elut certify 130 
mg. Ethyl acetate yielded the best impurity profile providing impurities with higher relative 
peak areas as seen in Figure 2. 
Although all four eluting solvents examined yielded acceptable profiles, ethyl acetate 
produced a profile for all the ten studied impurity peaks with reasonable relative peak area. 
Therefor ethyl acetate was the solvent of choice for the elution step. 
3.3 Assessment of different SPE columns 
Eight SPE columns from two manufacturers (Varian and International Sorbent 
Technology, ISn were evaluated. All SPE columns examined using the optimised pH 9 and 
the optimised eluting solvent, ethyl acetate. After evaluation of the determined impurity 
profiles, Varian C 18 (200mg) provided the best impurity profile with the highest relative 
peaks areas as it is shown in the bar chart in Figure 3. 
3.4 Blank Extracts 
A blank sample consisting of only a buffer solution at pH 9 was extracted with the 
optimised eluting solvent, ethyl acetate and by the optimised SPE column, Varian Bond Elut 
C 18 200m. This step was necessary to be certain that all the peak taken for the evaluation 
were not generated from any source other than the ecstasy homogenised powder. Figure 5 
demonstrates a chromatogram of a blank sample extracted with the conditions mentioned 
above. 
3.5 Stability of Extracts during Storage 
A demonstration of the stability of extracts during storage was done for an ecstasy 
sample extracted with optimised procedure. The sample was analysed by GC-FID four times 
over a period of four weeks. The sample was stored in the dark at 4°C for the whole period 
and was only out briefly for the analysis. Figure 6 illustrates the stability study of the extracts 
profile over the four weeks period. 
After four weeks of storage of extracts in the dark at 4°C, the impurity profiles showed 
no major changes and were still valuable for comparison purposes. 
3.6 Application to Case Samples 
Three different ecstasy tablets brought to the laboratory from different sources were 
crushed, homogenised and extracted with the optimised parameters. Figures 7a, 7b, and 7c 
show comparison of profiles of these different ecstasy samples. 
Sample 001 and 002 showed similar profiles with minimum variation indicating that 
they have originated from the same source. Samples 001 and 002 showed no similarities with 
sample 003 indicating that they cannot be from the same source. 
4. Condusion 
The optimisation of the solid phase extraction (SPE) procedure for the purpose of 
profiling impurities found in ecstasy tablets manufactured in clandestine laboratories was 
done. The determined optimum parameters for the SPE procedure were as follows: 
1. Buffers with pH 9 were found to be the optimum for extracting impurities of ecstasy 
tablets. 
2. The eluting solvent with most impurities extracted was ethyl acetate. 
3. Among all the eight SPE columns evaluated, Varian Bond Elut CI8 200mg produced the 
best impurity profile allowing for easy comparison of profiles of real samples. 
Blank samples were extracted using the optimised procedure to make sure that no 
impurities other than those present in the ecstasy sample were extracted and analysed. 
Extracts showed no major degradation after storing them in the dark at 4°C for four weeks 
and their profiles were still suitable for comparison purposes after this period. 
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ABSTRACT 
A method for profiling of ecstasy tablets through the use of fourier transform infrared 
spectroscopy (FTIR) was developed. Around 47 ecstasy tablets plus standards of MDMA, 
glucose, lactose, and caffeine were used for the study. Samples prepared as KBr disks were 
analysed directly without any extraction procedures or other sample preparations. Library search 
facilities were used to compare spectra using an algorithm of correlation coefficient. The library 
search provided best fits or closest matches from the library spectra to the unknown spectrum. A 
higher number means a closer match (1 being the highest and 0 being the lowest). 
Introduction 
Chromatographic instrumentation has been used to perform drug profiling, in particular 
gas chromatography with flame ionisation detection [1-3], isotope-ratio mass spectrometry [4-5], 
and HPLC [6-7]. Chromatographic methods are powerful tools for comparing drug seizures, but 
they do have their inherent limitations. Infrared spectroscopy and in particular fourier transform 
infrared, FTIR, can serve as a viable elimination technique for comparing drug seizures. Each 
exhibit has its own characteristic spectrum, and comparison between the different spectra gives a 
gross estimate of the similarity or dissimilarity between the different exhibits [8-10]. FTIR has 
some discriminating capability to classify powders into a large number of groups, and 
consequently can be used for gross comparison of ecstasy exhibits. FTIR has some advantages 
over chromatographic methods such as minimum sample preparations and faster analysis time 
(under 1 min./sample). 
Drug samples encountered in crime laboratories are normally exhibited in dosage units 
and presented as their own entities or as counterfeits of brand-name pharmaceutical products. 
Ecstasy is the common name for 3,4-methylenedioxy-methamphetamine (MDMA); a synthetic 
hallucinogenic amphetamine, which has become one of the most widely used controlled 
substances in Europe. It is almost always illicitly produced in clandestine laboratories and often 
exhibited in tablet dosage. 
This paper deals with the subject of ecstasy profiling (that is, attempt to carry out gross 
comparisons between ecstasy seizures) through the use of FTIR as a screening tool in drug 
profiling procedures. 
Experimental 
Materials 
Forty-seven ecstasy samples from twenty-four seizures were used in the experiment. The 
Forensic Science Service, Metropolitan laboratory, London, provided street samples of ecstasy 
tablets. Standards of MDMA, lactose, glucose and caffeine were maintained from Sigma. 
Sample Preparation and Instrumental Analysis 
Samples were prepared using KBr disks. Around 1 mg of sample was ground by pestle 
and mortar into a fine powder. Then about 300 mg of oven dried KBr were added and ground 
again to a fine homogeneous powder. The finely ground sample was then removed and placed in 
a 13mm KBr die to sandwich the mixture between two polished surfaces and press the KBr and 
sample into a disk. High pressure (12000kg) was then applied by means of a lever to coalesce 
the sample into a transparent or semi-transparent disk. Vacuum was applied to the die to remove 
entrained air, and to a limited extent, entrained moisture. As entrained moisture can cause the 
finished disk to be opaque. The prepared disk was then mounted in the beam of the spectrometer 
for analysis. Infrared spectra were obtained using a Jasco FTIR-410 Spectrometer (lasco UK 
Ltd., Essex, UK). 
Spectra Comparison 
Once spectra for standards and all 47 ecstasy samples were obtained, comparisons of 
spectra using library search facility from a commercially available spectral program called 
Spectra Manager SSP-400 search program (Jasco UK Ltd., Essex, UK), were performed for the 
purpose of establishing similarity or dissimilarity between the different exhibits. An in-house 
library was created which contained spectra for standards and 47 ecstasy samples. The library 
search was done using an algorithm for correlation coefficient for comparison purposes. This 
method conducts a search by comparing the spectrum waveform of an unknown sample with the 
spectral waveforms of library spectra. The library search provides best fits or closest matches 
from the library spectra to the unknown spectrum. A higher number means a closer match (1 
being the highest and 0 being the lowest). The comparison procedure was based on two main 
elements, I} the library search results (best fit) and the visual comparison of spectra using an 
overlay diagram. 
Repeatability of Analysis 
To test the repeatability of spectra, a single sample was analysed as above ten times using 
the same procedure and parameters including sample preparation as a disk and analysis on FTIR. 
Statistical analysis was then performed to calculate percentage relative standard deviation 
(RSD). 
Comparison of tablets from different seizures 
Tablets from different seizures chosen randomly were analysed for the purpose of 
establishing common source. Each tablet was ground, extracted, and analysed separately to 
avoid cross contamination. The result spectra were compared by the use of library search 
facilities. 
Results and Discussion 
The aim of comparative analysis is the comparison of confi cated drugs fi f in stigati . 
purposes and court testimony. Drug intelligence involves two main tream with f"gard t 
comparative analysis or drug profiling. The first includes court cases such as sample/sample 
comparison and relating user to a dealer to prove conspiracy. The ec nd task II r drug 
intelligence involves establishing relationships between seizures and providing informati 11 11 
the networking of samples, which may be of use in investigating major trafficking p rati n . In 
such operation the laboratory may have to analyse many samples. FTIR analysis can b utili ed 
for such operation as an elimination tool for its sheer simplicity and short analy is time. 
Repeatability of Analysis 
After analysis of sample number (MOl) for ten times, reproducible spectra wer btain d 
and the calculation of percentage relative standard deviation (R D) h w d Ilent 
repeatability of results. The procedure included running a library earch on ten different p tra 
of sample (MOl) and using the fit factors (library scores) from the search re ult 
percentage RSD. Table 1 illustrates the statistical results for the repeatability tudy. 
Column Statistics Rc ults 
Mean of library scores 0.98 
Standard Deviation 0.0098 
Library score: minimum 0.974 
Library score: maximum 1 
n 10 
RSD (%) l.00 
Table 1. Statistical results for the repeatability study. 
The above study provided evidence of the excellent repeatability of our procedure. This 
shows that when using FTIR technique as a screening tool for drug comparison no false 
interpretation base on poor repeatability is made. 
Comparison of tablets from different seizures 
Comparison of spectra of samples from different seizures yielding different physical 
features such as colour and logos showed correlation of their spectra as seen in the example 
given in Figure 1 which shows an overlay comparison of two samples from different seizures. 
This technique can be used as a visual mean of comparing spectra of similar tablets from 
different seizures or comparing two different exhibits to establish similarity or dissimilarity. 
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Figure 1. An overlay of spectra of sample (MO 1) and sample (M26) 
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The above method is useful when only small amounts of exhibits are compared. In the 
case of large amounts of seizures or in the case of building a database with many spectra 
included and samples to be related or grouped into smaller clusters, then use of computer 
software is faster and more useful. Visual comparison is still handy as a confirmation t lh. 
library search results. In Table 2 an example is given of a library search results wher a sp> tra 
of an unknown (confiscated ecstasy tablet) was compared with a database f peclra of street 
ecstasy tablets. 
Order of Fit Library Score ample Name 
1 0.977 M13 
2 0.971 M26 
3 0.900 M32 
4 0.789 M10 
5 0.769 Ml4 
6 0.761 M02 
Table 2. Search results of comparing an unknown against a library databa e for th cl e t mat h 
Figure 2 illustrates the library results in terms of spectra. ampJe (M 13), (M2 ), an th 
unknown showed similarities indicating their relation to a common batch. 
Theses findings can be used positively to save time and Jaboratory work. Th r ult r 
the FTIR analysis may be used to eliminate many samples before proceeding to m re n ili 
procedures such as chromatography. FTIR results can also provide a gro stimati n f th 
different groups or profiles of drugs under investigation. 
Although FTIR technique is not sensitive enough to detect minut am unt f 
compounds such as manufacturing impurities, which are essential to the pr filing pr , it c n 
still be a useful tool when its results are combined with other analytical pr cedur in luding 
physical analysis and microscopy and information from police investigati ns. 
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Figure 2. Library search results of matching an ecstasy exhibit (unknown) with a database of 
spectra of other ecstasy samples. 
Conclusion 
FTIR can be a very useful tool for comparative analysis of confiscated drugs for its sheer 
simplicity with regard to sample preparation and instrumental procedure, short analysis time and 
excellent repeatability of results. The library search facility provided a way to compare two 
samples and relate a sample to a group of samples from different seizures analysed previously. 
Comparative studies on confiscated ecstasy tablets through the use of FTIR when combined with 
a study of the physical features of tablets such as colour, size, logo, and microscopic analysis are 
possible and help provide information for the drug investigation process. 
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The objectives of this paper are to infer the area of drug profiling or comparative 
analysis of drugs of abuse and provide an overview of the developments on this 
science including the different approaches and procedures performed. In addition to 
identifying the presence of a specific controlled drug in an exhibit and measuring its 
concentration, forensic drug laboratories are requested in certain cases or as a routine 
to provide additional information that may be helpful to the investigation process. On 
the basis of their chemical and physical characteristics, seized drugs may be profiled 
and linked to common sources or routes of distribution. Not only does this allow the 
matching of samples in local cases of dealing but also provides intelligence 
information on the origin and distribution of samples Scientists, specialising in illicit 
drug analysis in criminal or other analytical laboratories have been using many 
different approaches in the area of illicit drug characterisation I profiling since the 
early 1970s. These approaches varied according to the drug nature and the analytical 
philosophy or needs. Samples coming into laboratories in tablets or capsule form are 
usually subjected to physical analysis or so called "ballistics". Other exhibits such as 
powders are subjected to chemical analysis, which can be organic or inorganic. 
Inorganic analysis of illicit drugs is concerned with the determination and comparison 
of the elemental content in exhibits. Organic analyses on the other hand are more 
varied with different types of analysis and approaches available to the forensic 
chemist including the following: 
1. Determination and quantification of impurities or minor components present in the 
seized drug, which originate from precursors, natural raw materials, and reaction 
by-products. 
2. Measurement of naturally occurring isotopic ratios. 
3. Determination of diastereoisomeric or enantiomeric composition of drug exhibits 
4. Determination of residual solvents for comparative analysis 
5. Analysis of the controlled drug(s) and cutting agents 
6. Drug profiling using infrared spectrometry 
Impurity profiling procedures have by far dominated the illicit drug comparison 
methods used in forensic laboratories around the world. Two main approaches have 
been reported, (i) identification of trace impurities for establishing synthetic routes 
and identification of precursor chemicals used in synthesis and (ii) comparing 
impurity profiles (chemical signatures) to establish drug origin, grouping, and sample-
to-sample comparison. 
